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ABSTRACT 
 
Preeclampsia remains a major cause of maternal and perinatal morbidity and mortality.  
Its exact aetiology is still obscure.  
Objectives: The objective of this case control prospective study which was conducted in 
Khartoum Teaching Hospital during the period (2007-2008) was to study the role of 
cytokines imbalance and oxidative stress in the pathogenesis of preeclampsia.  
Methodology:  The levels of interferon gamma (IFN-γ), as Th1 cytokine and interleukin-
4 (IL-4), interleukin-10 (IL-10) as Th2 cytokines were determined using Enzyme-linked 
immunosorbent assay (ELISA) in sera from 33 women with preeclampsia (at presentation 
and 7 days later) and 32 women with normal pregnancy as a control group. 
In order to study the effect of the oxidative stress on pathogenesis of preeclampsia, the 
activity levels of the erythrocyte antioxidant enzymes; glutathione peroxidase, catalase 
and superoxide dismutase were determined in 37 women with preeclampsia compared to 
38 women with normal pregnancy in the third trimester using ELISA, and omega-3 
(Eicosapentaenoic acid ; EPA & Docosahexaenoic acid; DHA) and omega-6 (arachidonic 
acid) profiles in three erythrocyte membrane phospholipids fractions; 
phosphatidylethanolamine (PE), phosphatidylcholine (PC) and sphyngomyelin, using gas 
chromatography. Further more, the plasma antioxidant vitamins; retinol and α-tocoferol, 
were also determined using HPLC. 
Results: at presentation, the levels of IFN-γ and IL-4 were slightly—not statistically 
significant— higher in the women with preeclampsia whereas IL-10 was significantly 
higher in the women with preeclampsia (P=0.002). Seven days later the women with 
preeclampsia had significantly lower levels of IFN-γ (P=0.035) and IL-4 (P=0.000) and 
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significantly higher levels of IL-10 (P=0.000). There were no significant differences in 
the levels of the three antioxidant enzymes in preeclamptic women compared to women 
with normal pregnancy. Women with mild preeclampsia (Diastolic blood pressure (DBP) 
< 110) have slightly higher (not statistically significant) level of activity of erythrocyte 
glutathione peroxidase, and lower activity levels of catalase and superoxide dismutase 
compared to women with severe preeclampsia (DBP≥ 110). A significantly negative 
correlation was observed between the activity of glutathione peroxidase and diastolic 
blood pressure, r= -0.371, P = 0.02. In the three phospholipids fraction (PE, PC & 
sphyngomyelin), the mean level of EPA was significantly higher in women with 
preeclampsia than the control group P = 0.012, 0.000, 0.000 respectively.  The mean level 
of DHA was significantly higher in women with preeclampsia than the control group, P= 
0.04, 0.046, 0.000 respectively. The mean level of arachidonic acid was only significantly 
higher in women with preeclampsia in the sphyngomyelin fraction P=0.000. When 
comparing women with mild and severe preeclampsia there was no statistically 
significant difference in fatty acids profiles. The median level of α-tocopherol was 
significantly higher in women with preeclampsia than the control group, P = 0.026. No 
significant difference was noted between the two groups regarding retinol level. 
Conclusion: The study findings do not support oxidative stress, but are in favor of 
involvement of cytokines imbalance in the pathogenesis of preeclampsia.  
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 .ﻤﺴﺒﺒﻪ
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 .  ﻟﻠﺤﻤلﺘﺤﺩﻴﺩ ﺍﻟﻌﻼﻗﺔ ﺒﻴﻥ ﻫﺫﻴﻥ ﺍﻟﺴﺒﺒﻴﻥ ﻭﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻤﺼﺎﺤﺏ 
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ﻀﻰ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ  ﻤﻥ ﻤﺭ33  ﻓﻲASILE ﺒﻭﺍﺴﻁﺔ ﺘﻘﻨﻴﺔ   2hT senikotyc ﻜﺄﻤﺜﻠﺔ ﻟـ
  . ﺴﻴﺩﺓ ﺫﻭﺍﺕ ﺤﻤل ﻁﺒﻴﻌﻲ ﻜﻤﺠﻤﻭﻋﺔ ﻀﺎﺒﻁﺔ23ﺍﻟﻤﺼﺎﺤﺏ ﻟﻠﺤﻤل ﻤﻘﺎﺭﻨﺔ ﻤﻊ 
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 ﻓﻘﺩ CPﺃﻤﺎ ﻓﻰ ﺸﻕ .  ﻋﻨﺩ ﺫﻭﺍﺕ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻤﻔﺭﻁAAﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺭﻀﻲ ﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉ 
ﻰ ﻤﺠﻤﻭﻋﺔ ﻭﻓ. ﻋﻨﺩ ﺍﻟﻤﺭﻀﻰ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﻀﺎﺒﻁﺔAPE,AHD ,AAﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉ ﻤﻌﺩل  
 ﻓﻲ AAﻋﻨﺩ ﺍﻟﺤﻭﺍﻤل ﺫﻭﺍﺕ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻤﻔﺭﻁ ﻭﺯﻴﺎﺩﺓ APE,AHDﺍﻟﻤﺭﻀﻰ ﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉ 
 ﻓﻲ ﻤﺠﻤﻭﻋﺔ  APE,AHD ,AA  ﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉnileymognyhpS ﺸﻕ ﻭﻓﻰ.  ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻷﺨﺭﻯ
ﻓﻲ ﺍﻟﺤﻭﺍﻤل ﺫﻭﺍﺕ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻤﻔﺭﻁ  ﻭﺍﻟـ  APE ,AAﺍﻟﻤﺭﻀﻰ ﻭﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉ ﻤﻌﺩل 
  . ﻋﺔ ﺍﻷﺨﺭﻯﻓﻲ ﺍﻟﻤﺠﻤﻭ AHD
 ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺔ loniterﻭﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻔﻴﺘﺎﻤﻴﻨﺎﺕ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻜﺴﺩﺓ ﻓﻘﺩ ﺘﻼﺤﻅ ﺍﺭﺘﻔﺎﻉ ﻤﻌﺩل 
 ﻓﻰ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺭﻀﻲ  ﻭﻓﻰ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺭﻀﻲ ﻓﻘﺩ ﺘﻼﺤﻅ αlorehpocot-ﺍﻟﻀﺎﺒﻁﺔ ﻭﺍﺭﺘﻔﺎﻉ 
  ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﺍﻟﺤﻭﺍﻤل ﺫﻭﺍﺕ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ αlorehpocot- ﻭloniterﺍﺭﺘﻔﺎﻉ ﻤﻌﺩل ﺍﻟـ 
  . ﻏﻴﺭ ﺍﻟﻤﻔﺭﻁ
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Introduction and Literature Review 
 
 
 
1.1 definition and incidence of preeclampsia 
 
Pre-eclampsia is a potentially serious condition that occurs in 2–7% of all pregnancies 
[1], and can be life threatening for both the mother and child. It is defined as new onset, 
persistent hypertension after 20 weeks of gestation in association with significant 
proteinuria [2]. But this simple clinical definition gives little idea of the complexity of the 
disorder. This common disorder, which is more prevalent in first pregnancies, is 
associated with the highest maternal and fetal morbidity and mortality of all pregnancy 
complications, with 90% of the most serious outcomes occurring in developing countries 
[3]. Pre-eclampsia can present as asymptomatic hypertension and proteinuria at one end 
of the spectrum to multi-organ failure at the other. The precise origins of the disease 
remain enigmatic, but the placenta undoubtedly plays a role since delivery inevitably lead 
to rapid recovery. It is a complex disorder caused by a series of nutritional, environmental 
and genetic factors that lead to the creation of an imbalance between the free radicals 
nitric oxide (NO), superoxide (O2−) and peroxynitrate in the vascular endothelium [4]. 
Preeclampsia can occur at anytime after approximately 20 weeks of gestation, and 
because delivery is the only cure, this common complication of pregnancy is a major 
cause of premature delivery. 
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1.2 Criteria for diagnosis: 
Diagnostic criteria for preeclampsia include new onset of elevated blood pressure and 
proteinuria after 20 weeks of gestation. Features such as edema and blood pressure 
elevation above the patient’s baseline no longer are diagnostic criteria [3, 4]. Severe 
preeclampsia is indicated by more substantial blood pressure elevations and a greater 
degree of proteinuria. Other features of severe preeclampsia include oliguria, cerebral or 
visual disturbances, and pulmonary edema or cyanosis [3, 4]. Diagnosis becomes less 
difficult if physicians understand where preeclampsia “fits” into the hypertensive 
disorders of pregnancy. These disorders include chronic hypertension, preeclampsia-
eclampsia, preeclampsia superimposed on chronic hypertension, and gestational 
hypertension, [4]. Chronic hypertension is defined by elevated blood pressure that 
predates the pregnancy, is documented before 20 weeks of gestation, or is present 12 
weeks after delivery [4].  In contrast, preeclampsia-eclampsia is defined by elevated 
blood pressure and proteinuria that occur after 20 weeks of gestation. Eclampsia, a severe 
complication of preeclampsia, is the new onset of seizures in a woman with 
preeclampsia. Eclamptic seizures are relatively rare and occur in less than 1 percent of 
women with preeclampsia [5]. 
1.2.1 Preeclampsia 
Preeclampsia is diagnosed according to the criteria of the international society for the 
study of hypertension in pregnancy, previously normotensive women with two repeat (4 
hours apart) diastolic blood pressure measurements of 90 mmHg or greater after the 20th 
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week of gestation, plus proteinuria of more than 300 mg/l in 24 hours as measured 
quantitatively or, ≥2+ protein by dipstick in two repeat measurements (4 h apart)  
1.2.2 Severe preeclampsia 
Blood pressure: 160 mm Hg or higher systolic or 110 mm Hg or higher diastolic on two 
occasions at least six hours apart in a woman at bed rest 
Proteinuria: 5 g or more of protein in a 24-hour urine collection or 3+ or greater on urine 
dipstick testing of two random urine samples collected at least four hours apart Other 
features: oliguria (less than 500 mL of urine in 24 hours), cerebral or visual disturbances, 
pulmonary edema or cyanosis, epigastric or right upper quadrant pain, impaired liver 
function, thrombocytopenia, intrauterine growth restriction 
1.3 Cytokines: 
Although reductions in blood flow to the uteroplacental unit are known to result in 
cardiovascular and renal abnormalities consistent with the pathophysiological features of 
human preeclampsia, the physiological mechanisms linking placental ischemia with the 
abnormalities in the maternal circulation are unclear. [6,7]. Several lines of evidence 
support the hypothesis that the ischemic placenta contributes to endothelial cell 
activation/dysfunction of the maternal circulation by enhancing the synthesis of cytokines 
such as tumor necrosis factor-α [8].  Cytokines are small secreted proteins which mediate 
and regulate immunity, inflammation, and hematopoiesis. They must be produced inside 
the body in response to an immune stimulus. They generally (although not always) act 
over short distances and short time spans and at very low concentration. They act by 
binding to specific membrane receptors, which then signal the cell via second 
messengers, often tyrosine kinases, to alter its behavior (gene expression). Responses to 
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cytokines include increasing or decreasing expression of membrane proteins (including 
cytokine receptors), proliferation, and secretion of effectors molecules. Cytokine is a 
general name; other names include lymphokine (cytokines made by lymphocytes), 
monokine (cytokines made by monocytes), chemokine (cytokines with chemotactic 
activities), and interleukin (cytokines made by one leukocyte and acting on other 
leukocytes). Cytokines may act on the cells that secrete them (autocrine action), on 
nearby cells (paracrine action), or in some instances on distant cells (endocrine action). It 
is common for different cell types to secrete the same cytokine or for a single cytokine to 
act on several different cell types (pleiotropy). Cytokines are redundant in their activity, 
meaning similar functions can be stimulated by different cytokines. Cytokines are often 
produced in a cascade, as one cytokine stimulates its target cells to make additional 
cytokines. Cytokines can also act synergistically (two or more cytokines acting together) 
or antagonistically (cytokines causing opposing activities). Their short half life, low 
plasma concentrations, pleiotropy, and redundancy all complicated the isolation and 
characterization of cytokines [9]. Searches for new cytokines are now often conducted at 
the DNA level, identifying genes similar to known cytokine genes. 
It is believed that the imbalance of the Th1/Th2 type responses, with a shift towards a 
Th1 response, may be involved in the etiology of preeclampsia [10], but the results on the 
Th1/Th2 in preeclampsia were inconsistent with each other. An elevated plasma level of 
Th2 type cytokines such as IL-4 was observed in preeclamptic patients [11]. No 
difference was found in Th1-cytokine production in peripheral blood and fetal cord blood 
between preeclamptic patients and normal pregnancies [12, 13]. In addition, CD8+ T (Tc) 
cells can differentiate into type 1 (Tc1) cells, producing mainly IFN-γ, and type 2 (Tc2) 
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cells, producing mostly IL-4, IL-5, and IL-10. The Tc1/Tc2 balance also can modulate 
the type 1/type 2 immunity [14]. 
1.4 T helper cells (Th cells): 
T helper (Th) cells can be divided according to the pattern of cytokines that they release 
into; Th1 cells, which release inflammatory cytokines such as interleukin-2 (IL-2) 
interferon gamma (IFN-γ) and tumor necrosis factor-β (TNF-β), induce cellular 
immunity, while Th2 cells, which release anti-inflammatory cytokines such as IL-4, IL-5, 
IL-6 and IL-10, induce antibody production [15]. Previous studies have suggested that in 
normal pregnant women, cytokines produced by Th2 cells predominate over those 
produced by Th1 cells, resulting in the maintenance of pregnancy [16-17]. 
1.5 Tumour necrosis factor alpha (TNF-α):  
Is a multifunctional proinflammatory cytokine that is involved in the pathogenesis of a 
large number of autoimmune and inflammatory human diseases.  The TNF-α gene is 
located in the chromosomal region 6p21.1–21.3, next to the major histocompatibility 
complex. Increased TNF-α expression in adipose tissue is associated with human obesity 
[19]. TNF-α act in a paracrine manner to interfere with insulin signalling by inhibiting 
autophosphorylation of the insulin receptor in fat and muscle cells [20]. It has been 
suggested to play an important role in insulin resistance and various components of the 
metabolic syndrome [19, 21]. Preeclampsia is a common and complex disease with a 
familial nature and a genetic background [22]. Impaired maternal immune response and 
different features of the metabolic syndrome, including insulin resistance, obesity, 
dyslipidemia and an increased risk of cardiovascular diseases are also characteristics of 
pre-eclampsia [23]. In addition, previous studies have demonstrated elevated circulating 
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concentrations of TNF-α in patients with severe preeclampsia and intrauterine growth 
restriction [24-27], and increased expression of the TNF-α gene in patients with 
preeclampsia [28, 29]. TNF-α has also been shown to affect early events in pregnancy, 
leading to failed trophoblast invasion and placentation [30]. 
1.6 Interferon gamma (IFN-γ): 
IFN-γ may be considered a polypeptide hormone primarily because of its ability to 
transduce signals from one cell type to the other through diverse effects. The wide range 
of cellular responses to IFN-γ include proliferation, apoptosis, leukocyte-endothelial 
interactions, up-regulation of inducible nitric oxide synthase production in macrophages 
(Thereby increasing reactive oxygen species production), tryptophan metabolism, 
mediation of antigen presentation by class I and II MHC complexes, and regulation of 
numerous genes whose functions are yet to be identified [31, 32]. IFN-γ functions by 
binding to the receptor heterodimers; IFN- γ R1 and -2; IFN- γ R1 has a ligand-binding 
site, and IFN-γ R 2 facilitates signaling via Janus kinase-signal transducer and activator 
of transcription pathways [33, 34]. Recent genetic and immunological experiments have 
established that the proliferative or cytotoxic effect of IFN- γ is primarily determined by 
the relative density of IFN- γ R1 and -2 on the T cell surface [35-37]. Despite extensive 
immunological studies, very little is known about the placental regulation of expression 
of IFN- γ and its receptors in human pregnancy, except that IFN- γ R1 is localized in 
placenta throughout pregnancy [38]. 
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1.7 Interleukin-10 (IL-10) 
IL-10 is an important anti-inflammatory cytokine in pregnancy that promotes the 
termination of Th1 inflammatory rejection reactions against the fetal-placental unit. In a 
small number of preeclampsia cases, high levels of IL-10 are seen both in the placenta 
and in peripheral blood, which might be a compensatory response to elevated levels of 
IFN-γ, TNF-α, IL-2 and IL-12 [39-41]. On the other hand, IL-10 deficiency and an 
increase of TNF-α expression in the placenta and decidua are observed in preeclampsia 
compared to those with a normal pregnancy. This was interpreted as a modified immune 
balance consistent with inflammatory responses in preeclampsia [42]. This suggests that 
coupling of IL-10 deficiency and inflammatory signals at different stages of pregnancy 
may contribute to worse clinical conditions, including preeclampsia [43]. 
1.8 Interleukin-4 (IL-4): 
Is one of type II cytokines (Th2 cytokines), which also include IL-5 and IL-10, their 
function is to down regulate proinflammatory immune responses mediated by type 1 
cytokines. Elevated plasma level of Th2 type cytokines such as IL-4 was observed in 
preeclamptic patients [11]. 
Th1-type cytokines such as a-tumor necrosis factor (TNF-α), interferon gamma (IFN-γ) 
and interleukin 2 (IL-2) induce trophoblastic apoptosis, restrain differentiation and 
invasion of trophoblast, and thus may be involved in the incomplete invasion of 
trophoblast to spiral arteries and shadow implantation of placenta that are integral 
pathologies of preeclampsia [44]. On the other side, Th2 cytokines such as IL-4 and IL-
10 stimulate the differentiation and proliferation of the trophoblast. 
 
 
 27
1.9 Basic immunology 
The human immune system can be divided into innate and adaptive immunity. Innate 
immunity provides a rapid and first line of defense against invading microorganisms. The 
major cell types included in innate immunity are macrophages, natural killer (NK) cells 
and the granulocytes: mast cells, neutrophils, eosinophils and basophils. 
These cells recognize microorganisms by their pattern-recognition receptors (PRRs) and 
they respond immediately by phagocytosis of microorganisms, eradication of infected 
cells, and cooperation with the adaptive immune response. The innate immune cells 
initiate immune responses and start to direct the adaptive immune responses, as well as 
aiding the adaptive immune response in the removal of pathogens targeted by the 
adaptive immune response. It takes 4–7 days before the initial adaptive immune response 
takes effect, and during this time the innate immune response has a critical role in 
controlling infections. Activated macrophages and NK cells secrete cytokines and 
chemokines, which initiate the inflammatory response and aid the destruction of 
phagocytosed particles. Furthermore, the macrophages have the capacity to present 
antigens from phagocytosed particles. The adaptive immunity reacts slower than the 
innate immunity, but has more long-lived and highly evolved antigen-specific protective 
responses, such as antibody production and cell-mediated immunity, Tosi (2005) [45]. 
The cells included in adaptive immunity are B- and T-lymphocytes, and these cells are 
also responsible for the immunological memory. B-lymphocytes are involved in the 
humoral defense against extracellular antigens by producing specialized antibodies upon 
stimulation; furthermore, these cells have the capacity to present antigens to the T-cells. 
A “helping” T-cell response is needed to induce B-cell proliferation and differentiation 
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toward protein antigens. T lymphocytes, with the β-receptor, have a cell-mediated 
response where they respond to a foreign antigen presented on human leukocyte antigen 
(HLA). T-cells destroy intracellular pathogens by killing infected cells and by activating 
macrophages, as mediated by the Th1 subset. However, T-lymphocytes also have a 
central role in the destruction of extra cellular pathogens by activating B cells, and this is 
the specialized role of the second subset of CD4+ T-cells, called Th2 cells. Only a few 
antigens with special properties can activate naïve B lymphocytes on their own. Most 
antigens require an accompanying signal from helper T-cells before they can stimulate B-
cells to proliferate and differentiate into cells secreting antibody. The T-lymphocytes 
expressing α, β-receptors are further divided into CD4+ T helper cells and CD8+ 
cytotoxic T-cells, depending on their type of antigen recognition and subsequent action. 
Cytotoxic T-cells mediate their function by “docking” onto a cell presenting foreign 
peptide antigen on HLA class I molecules, and induce apoptosis of that cell. T-helper 
cells direct the reaction of other cells of the innate and adaptive immune system more 
than they participate themselves in an immune reaction. They recognize antigens 
presented on HLA class II molecules on antigen-presenting cells (APC). The T-helper 
cells practice their effector functions on other immune cells by secreting cytokines. The 
signature cytokine of human Th1 cells is interferon gamma (IFN-γ) and lymphotoxin 
(LT), while Th2 cells are defined by their production of interleukin IL-4, IL-5 and IL-9. 
The cytokines produced by these T-cells determine the effector function as well as 
participate in the development and expansion of each subset. That is, the IFN-γ produced 
by the Th1 cells promotes further Th1 differentiation and inhibits Th2 cells. Vice versa, 
the IL-4 produced by the Th2 cells promotes Th2 differentiation and, accompanied by the 
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anti-inflammatory IL-10, produced mainly by activated macrophages, inhibits the 
activation of Th1 cells. Thus, the Th1 and Th2 cells amplify their own subset and each 
cross regulates the other. Once an immune response develops along one pathway, it 
becomes increasingly polarized in that direction. However, immune cells other than Th1 
and Th2 cells as well as other cells in the body can produce cytokines. Therefore, in 
general terms of the entire immune system the Th1/Th2 responses are called type 1 and 
type 2 responses. The main effector function of the Th1 cells is phagocyte-mediated and 
cytotoxic defense against infections, especially with intracellular microbes. The main 
effector function of the Th2 cells is IgE- and eosinophil/mast cell-mediated immune 
reactions, as well as inhibition of phagocytosis [46, 47]. Pro- and anti-inflammatory 
cytokines, just as for the Th1/Th2 concept, the balance between the effects of pro- and 
anti-inflammatory cytokines is thought to determine the outcome of the disease [46, 48]. 
The timing and the location of pro and anti-inflammatory cytokines plays a role in the 
outcome of a disease, as shown by Widhe et al. (2002) [49].  
As reviewed by Dinarello (2000) [48], the concept of pro- and anti-inflammatory 
cytokines is based on whether genes coding for the synthesis of mediator molecules are 
up-regulated during an immune response. Pro-inflammatory genes are those coding for 
phospholipase A2 (PLA2), cyclooxygenase (COX-2) and inducible NO synthase, since 
these are the enzymes that increase the synthesis of platelet-activating factor and 
leukotrienes, prostanoids and NO. The cytokines IL-1 and TNF (and in some cases IFN-
γ) are effective in stimulating the expression of these genes. Chemokines, such as IL-8, 
are chemotactic and facilitate the passage of leukocytes into the tissue from the vascular 
compartment. In addition, they are also pro-inflammatory molecules. Anti inflammatory 
 30
cytokines block or suppress the intensity of the pro-inflammatory cascade. For example, 
IL-4, IL-10, IL-13 and TGF-β suppress the production of IL-1, TNF, IL-8 and vascular 
adhesion molecules. Therefore, the balance between the effects of the pro-inflammatory 
and anti-inflammatory cytokines is thought to determine the outcome of the disease. 
1.10 Regulatory T-cells  
Another cell type involved in the outcome of immune reactions is the regulatory T-cell. 
There are different types of regulatory T-cells identified up to now and more subsets are 
continuously being discovered; however, one type of regulatory T-cells (Treg) are the 
CD4+CD25+ self-reactive T-cells which suppress other, harmful, auto-reactive T-cells by 
cell–cell contact and/or by producing IL-10 and TGF-β [50, 51]. The suppression 
mediated by regulatory T-cells is essential for the induction and maintenance of tolerance 
to self-antigens [50, 51]. Furthermore, T-helper lymphocytes producing high amounts of 
TGF-β, IL-10 and IL-4 have been termed as type 3 cells (Th3) [47, 52]. These cells also 
display regulatory functions in that they actively suppress antigen-specific responses after 
re-challenge with antigens. The cytokine secretion in response to antigen-specific 
stimulation inhibits the development of Th1 responses, and is associated with low levels 
of antibody and a virtual absence of inflammatory T-cell responses [52]. Besides 
preventing autoimmune T-cell responses, Tregs are also believed to be involved in the 
suppression of other inflammatory responses, e.g., infection and allergy. 
1.11 Immunology of normal pregnancy: 
Among all the other changes that a woman’s body undergoes during pregnancy, her 
immune system also has to undergo adaptations, since the maternal immune system likely 
plays a part in the placentation process as well as in the maintenance of pregnancy. In the 
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late luteal phase of the menstrual cycle and early gestation, the decidua is infiltrated by 
large numbers of CD56-positive NK-cells, but their numbers decline as the pregnancy 
progresses. The number of macrophages and T-cells remains relatively constant 
throughout gestation. CD56 cells have been proposed as promoting trophoblast growth 
and invasion by secreting cytokines, especially leukemia inhibitory factor (LIF), in 
response to the HLA-G expressed on cytotrophoblastic cells. Furthermore, it has been 
shown that the expression of (LIF) is associated with Th2 responses [53]. At the adaptive 
level it is believed that the immune system during normal pregnancy is associated with a 
Th2 shift, as suggested by Wegmann et al. (1993) [16]. The idea of weakened cell-
mediated immunity and increased humoral immunity is supported by clinical findings in 
pregnant women, where women with rheumatoid arthritis (RA), a cell-mediated 
autoimmune disorder, experience temporary remission of symptoms during pregnancy 
[16, 54, 55]. On the other hand, women with systemic lupus erythematosus (SLE), an 
autoantibody mediated disease, may experience worsened symptoms of the disease 
during pregnancy [16, 56]. Furthermore, Sacks et al. (1999) [57] has proposed that the 
alterations of adaptive immune responses during pregnancy are accompanied by 
increased innate immune responses. A majority of women experiencing unexplained 
recurrent spontaneous abortions (RSA) shows increased peripheral blood mononuclear 
cell (PBMC) production of IFN-γ and TGF-β in response to trophoblast antigens, while 
PBMCs from women not prone to RSA respond with IL-10, as reviewed by Raghupathy 
(1997) [58]. In addition, Piccinni et al. (1998) [53] showed that decidual cells from 
women with RSA had a lower production of IL-4, IL-10 and LIF in comparison with 
Decidual cells from normal pregnant women. This suggests that Th2 type immune 
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responses play a significant role in successful gestation and that Th1 type of immune 
responses are inconsistent with successful pregnancies [16, 53]. Furthermore, Wegmann 
et al. (1993) [16] also report a Th2 cytokine dominance in decidual cell culture 
supernatants from normal pregnancy. 
Further laboratory findings of increased production of IL-4 and IL-10 and decreased 
production of IL-2 and IFN-γ from phytohemagglutinin (PHA, mitogen)-stimulated 
PBMCs supports the idea of a Th2 shift during normal pregnancy [59]. Reinhard et al. 
(1998) [60] also found increased levels of IL-4 and decreased levels of IFN-γ and IL-2 in 
T-lymphocytes from women with normal pregnancies compared to non-pregnant women. 
In addition, Ho et al. (2001) [61] detected higher spontaneous production of IL-10 than 
IFN-γ in PBMC cultures from normal human pregnancies. More specifically, the 
maternal immune system has been shown to have an increase of fetus-specific Th2 type 
responses, i.e., increased numbers of IL-4-secreting PBMCs in response to paternal 
antigen in normal human pregnancies as compared to non pregnant controls [62]. Taken 
together, these findings suggest that normal pregnancy requires a Th2/anti-inflammatory 
type of immunity, at least directed toward the fetus and placenta, while pregnancy 
complications such as RSA could be due to a skewed Th1/pro-inflammatory type of 
immunity [61, 62]. 
1.12 Immunology of preeclampsia: 
In contrast to normal pregnancy, there are indications of increased inflammatory 
responses and also of an immune deviation toward Th1 in the established preeclamptic 
pregnancy. Roberts et al. (1989) [63] were one of the first to suggest that mediators 
released from the preeclamptic placenta are responsible for the endothelial damage seen 
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in preeclampsia. Subsequent to the damage, the injured endothelium initiates a 
dysfunctional cascade of coagulation, vasoconstriction and intravascular fluid 
redistribution that results in the clinical syndrome of preeclampsia.  
Indeed, preeclampsia is associated with systemic maternal inflammation [64], which at 
the adaptive level has been suggested to be dominated by T-helper (Th) type 1 response, 
as reviewed in Saito and Sakai [18]. 
1.13 Th1/Th2 in preeclampsia   
Results from studies designed to test the Th1/Th2 hypothesis in preeclampsia have not 
been consistent. Saito et al. (1999a) [10] measured the number of Th1 (CD4+IFN-γ) and 
Th2 (CD4+IL-4+) cells during normal pregnancy and preeclampsia, and found that the 
Th2 cytokines dominated during normal pregnancy while Th1 cytokines dominated 
during preeclampsia. In the same study, the PBMC production of IFN-γ and IL-4 was 
measured and the secreted levels were found to correlate with the number of Th1/Th2 
cells. That is, normal pregnant women showed a significantly higher production of IL-4 
and lower production of IFN-γ than women with preeclampsia. Darmochwal-Kolarz et al. 
(1999) [65] has also found increased production of IFN-γ in stimulated PBMCs. In 
contrast, Gratacos et al. (1998) [66] found that the serum levels of IL-4 and IL-10 did not 
differ between women with normal pregnancies and women with preeclampsia. In line 
with this, Henriques et al. (1998) [67] were able to detect IL-4 in placentae, but were 
unable to detect any differences between placentas from preeclamptic pregnancies and 
those from normal pregnancies, while Omu et al. (1995)  [11] detected increased levels of 
IL-4 in serum from women with preeclampsia compared to normal pregnant women. 
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Furthermore, Daniel et al. (1998) [68] detected similar plasma levels of IFN-γ in between 
women with preeclampsia and women with normal pregnancies. 
Pro- and anti-inflammatory balance during preeclampsia, likewise as for the studies of 
Th1 and Th2 balance, the reports on pro- and anti-inflammatory cytokines in 
preeclampsia differ from each other. The plasma levels of the pro-inflammatory 
cytokines IL-6 and TNF-α have been shown to be increased during preeclampsia when 
compared to normal pregnancy [8, 69], although no differences were seen for IL-1β and 
IL-10 [8]. In addition, Kupferminc et al. (1996) [70] found increased levels of IL-6 in 
plasma from women with preeclampsia compared to those with normal pregnancies. In 
contrast, Al-Othman et al. (2001) [71] found no differences in the levels of IL-6 in 
maternal serum from preeclamptic pregnancies compared to normal pregnancies. 
Furthermore, in studies on plasma levels of IL-10 and TGF-β1 Benian et al. (2002) [72] 
found increased levels of these markers during preeclampsia as compared to normal 
pregnancy. On studies of the serum levels of IL-12, Dudley et al. (1996) [73] found 
increased levels of the p40 subunit of IL-12 in women with preeclampsia, but no 
differences in the intact p70 dimer between women with preeclampsia and those with 
normal pregnancies. Although the levels of IL-12 p70 did not always reach detection 
levels, Daniel et al. (1998) [68] found increased levels of the IL-12 dimer in plasma from 
preeclamptic women compared to normal pregnant women. When measuring the 
stimulated cytokine production in PBMC cell culture supernatants, Darmochwal-Kolarz 
et al. (1999) [65] found increased levels of IL-2 and decreased levels of IL-10 in PBMCs 
from women with preeclampsia compared to women with normal pregnancies. Gratacos 
et al. (1998) [66] measured the serum levels of granulocyte-macrophage colony-
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stimulating factor (GM-CSF) and found decreased levels during preeclampsia compared 
to normal pregnancy. Based on studies of murine pregnancies where this cytokine is 
found in high concentrations at the maternal– fetal interface and injection of high levels 
decreases fetal death in resorption prone animals, they suggested that GM-CSF may also 
be of importance in human pregnancy. Furthermore, Sacks et al. (1998) [74] found a 
pattern of increased cell surface markers and reactive oxygen species in leukocytes akin 
to that of sepsis in women with preeclampsia (Possible causes for the shifts in immune 
balance seen in preeclampsia). An earlier report has shown production of TNF-α in pure 
choriocarcinoma cell lines (Jar and JEG-3, equivalent to cytotrophoblastic cells) [75]. 
Furthermore, Wang and Walsh (1996) [76] found increased levels of TNF-α from 
preeclamptic placentas compared to placentas from normal pregnancies. These findings 
indicate that the placenta is involved in the production of TNF-α. The ischemia in the 
placenta during preeclampsia can also lead to the production and release of cytokines into 
the maternal circulation. As reviewed by Conrad and Benyo (1997) [8], it is highly 
possible that the ischemia leads to the production of TNF-α and IL-1. These cytokines are 
capable of producing endothelial cell activation and dysfunction. Apoptotic trophoblast 
and syncytiotrophoblastic microparticles are constantly shed from the placenta during 
pregnancy, with increased circulating levels during preeclampsia, as reviewed by 
Redmamm and Sargent (2003) [64]. Furthermore, it is possible that these trophoblastic 
cells might evoke an immune response in the mother. Curiously, Neale et al. (2003) [77], 
detected increased apoptosis of trophoblastic cell lines that were exposed to serum from 
preeclamptic women; this may in turn indicate a vicious circle involving the trophoblasts 
and general maternal systemic effects during preeclampsia, as detected by the influence 
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of their serum on the cell cultures. Furthermore, the excessive amounts of 
syncytiotrophoblastic microparticles might be the cause of the Th1 activation in 
preeclampsia Redmann and Sargent 2003) [64]. These particles have been shown to 
inhibit endothelial cell function and to cause them to release proinflammatory factors. In 
addition, the monocytes can take up and process these particles with the possible result of 
increased production of the proinflammatory cytokines TNF-α and IL-12, the latter 
inducing Th1. 
1.14 Preeclampsia and oxidative stress: 
1.14.1 The role of the placenta: 
The focus on the placental origin of pre-eclampsia led to the discovery that defective 
placentation is a likely predisposing factor in the evolution of the maternal syndrome. 
Placentation is the process by which the placental trophoblast invades the uterine wall; 
this occurs by cytotrophoblast invasion of the decidua and myometrium and, notably, of 
the maternal spiral arteries therein. This process has been found to be at fault in women 
with pre-eclampsia, as shown by histological examination of the placental bed, which has 
demonstrated partial failure of trophoblast invasion [78]. Because the invading 
trophoblast normally effects thinning of the vascular wall and thereby reduces utero-
placental vascular resistance, poor invasion of the spiral arteries will reduce blood flow to 
the placenta. Pregnant women at risk of pre-eclampsia often (but not always) demonstrate 
decreased blood flow in the uterine artery when assessed by analysis of the uterine artery 
Doppler waveform [79], which provides an indirect demonstration of the high resistance 
in the spiral arteries. It has long been hypothesized that poor placental blood flow sets up 
a chain of events, which culminates in the development of pre-eclampsia in a woman 
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susceptible to the disease. This has given rise to the ‘2-stage theory of pre-eclampsia’; the 
first stage is reduced placental blood flow and the second is the subsequent development 
of the maternal syndrome [80]. Several studies suggest that placental lipid peroxides are 
increased [81-83] and placental antioxidant protective mechanisms decreased in pre-
eclampsia [83, 84], indicating that the placenta may be the source for this imbalance in 
pro-oxidant/anti-oxidant activity. Whether placental hypoxia is the cause of this 
imbalance has still to be addressed, since it has been demonstrated that tissue hypoxia 
promotes lipid peroxidation in rats [85] and increases expression of xanthine oxidase, an 
enzyme which generates superoxide [86]. However, most of the literature describes 
increased reactive oxygen species generation after reperfusion of acutely ischaemic tissue 
[87, 88]. To date, a causative relationship between chronic placental hypoxia similar to 
that described in placenta in pre-eclamptic women and increased superoxide generation 
has not been established. Again, another possible scenario is that oxidative stress may be 
the result rather than the cause of pre-eclampsia, or that the process, once triggered by the 
‘unknown’ causative factor, becomes amplified in a vicious circle.  From early pregnancy 
the human placenta influences maternal homeostasis; it is rich in mitochondria and when 
fully developed consumes about 1% of the basal metabolic rate of the pregnant woman 
[89]. It is also highly vascular and is exposed to high maternal oxygen partial pressure. 
These characteristics explain, in part, the generation of superoxide, because about 5% of 
all electrons in the mitochondrial respiratory chain leak out of the mitochondria [90]. 
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1.14.2 Oxidative stress 
Oxidative stress in aerobic life can be defined as the imbalance between the generation of 
reactive oxygen species (ROS) and the rate of their consumption by antioxidants. 
Lipid per oxidation is a process that occurs normally at low levels in all cells and tissues. 
It involves conversion of unsaturated fatty acids to lipid hydro peroxides. This process 
can be initiated by free radicals, which are unstable molecules that possess an unpaired 
electron in their outer orbital. Following interaction between the lipid and a free radical, 
peroxidation chain becomes self-perpetuating, with the lipid hydro peroxide inducing the 
formation of more hydro peroxide [91]. The organism normally has anti-oxidative 
mechanisms that limit this process.  
1.14.3 Reactive oxygen species: 
 There is increasing evidence to suggest endothelial cell damage and dysfunction in the 
pathogenesis of preeclampsia [63]. although the actual cause of this endothelial damage 
is not well-known, neutrophils, through their ability to produce reactive oxygen species 
(ROS), have been implicated as likely candidates. [64]. Superoxide anions (O2−) have 
been shown to influence vascular tone either indirectly, by inactivating NO and reducing 
the release of prostacyclin, [92] or by directly contracting smooth muscle [93]. High 
concentrations of superoxide have been found to reorient the arachidonic acid pathway in 
cells toward the production of thromboxane A2, which is a potent stimulator of 
vasoconstriction and platelet aggregation [94].The imbalance between prostacyclin and 
thromboxane A2 is well-documented in preeclampsia [95]. Furthermore, neutrophil-
derived superoxide anions can damage vascular integrity and endothelial cell function 
[96]. In preeclampsia, investigators have demonstrated a significant increase in O2− 
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production by neutrophils. [74, 97, 98]. Thus, it seems plausible that the increased ROS 
produced by neutrophils may be important in mediating endothelial damage in 
preeclampsia. Neutrophils synthesize NO in addition to ROS from L-arginine by the 
enzyme NO synthase (NOS) [99]. The NO released by neutrophils has been documented 
to prevent neutrophil adhesion to the vascular endothelium, [100] to control aggregation 
of neighboring platelets [101] and, in the absence of endothelium injury, to produce a 
vasodilatory effect [102]. NO also reacts with O2− to yield the powerful peroxynitrite 
radical, which may alter vascular function [103]. In contrast, NO inhibits nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase activity and scavenges free radicals 
[104, 105]. Thus, NO can either scavenge O2− or be transformed by O2− into highly 
reactive nitrogen intermediates. In addition, NO is metabolized by a variety of other 
pathways. One is oxidation to nitrate and nitrite, [106] and the other is reduction by S-
nitrosoglutathione reductase to ammonia [107]. NO production in vivo is usually 
measured by the concentrations of nitrite and nitrate in plasma, serum, or urine. In 
preeclampsia, the data on nitrite levels in blood are controversial, with studies reporting 
reduced, [108], normal, [109], or elevated [110] nitrite levels. The circulating levels of 
nitrite and nitrate are affected by elimination, most of which occurs through the kidney, 
so renal changes in preeclampsia could affect circulating nitrite and nitrate levels.The 
generation of ROS from activated neutrophils has been shown to result in significant 
endothelial cell injury in a variety of disease states [111]. Several invitro studies have 
been performed to determine the mechanism of neutrophil-mediated cell injury [112, 
113]. In those studies, H2O2 or the hydroxyl radical were implicated as the oxidant 
responsible for cell injury. Neutrophils from women with preeclampsia produced 
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significantly greater endothelial cell injury than did neutrophils produced in other 
diseases. This finding indicates that neutrophils from women with preeclampsia damage 
endothelial cells directly. Catalase, which catalyzes the conversion of H2O2 to oxygen and 
water, inhibited neutrophil-mediated endothelial cell injury in preeclampsia, suggesting 
that H2O2 may serve as a mechanism of neutrophil-mediated endothelial cell injury in 
preeclampsia. In contrast, SOD, which dismutates O2− excess to H2O2, did not affect 
neutrophil-mediated endothelial cell injury. Two possible explanations should be 
considered. First, H2O2 is converted by endogenous catalase to water, and regulation of 
any of these endogenous enzyme systems may modulate H2O2 levels. Second, the decline 
in O2− is expected to reduce the generation of ONOO, which has also been found to 
mediate cytotoxicity, and consequently to reduce endothelial cell injury mediated by 
ONOO. Under normal circumstances, the relatively high abundance of the SOD 
enzyme dismutates O2− to H2O2; however, when NO is produced in large quantities, a 
significant amount of O2− reacts with NO to produce ONOO [114].The production of 
ONOO in neutrophils has also been found to mediate cytotoxicity [99].  Oxidative 
stress, resulting from the imbalance between increased reactive oxygen species (ROS) 
formation and defects in antioxidant defense mechanisms, has been implicated in the 
pathogenesis of many vascular disorders, including atherosclerosis, diabetes, and 
hypertension. Cells of the human body are continually attacked by ROS, which arise as 
natural by-products of normal cellular energy production or are generated in large 
amounts in special situations. In normal pregnancies, there is an increase in free radical 
production and lipoperoxidation towards the end of pregnancy when compared with non-
pregnant women [115]. Others propose that endothelial dysfunction could originate from 
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oxidative stress in the placenta, for which there is strong evidence [116]. And which is 
likely to arise from hypoxia, or hypoxia/ reperfusion, both of which may occur because of 
failure of myometrial small artery remodeling. Indeed an elegant in vitro study of normal 
placenta has shown oxidative damage in syncytiotrophoblast after hypoxia/ 
reoxygenation [117]. The oxidative stress and microparticle hypotheses are not mutually 
exclusive as oxidative stress has been shown to increase apoptosis and thereby may lead 
to microparticle release [118]. Placental hypoxia and reoxygenation, through oxidative 
stress may also stimulate placental synthesis of cytokines e.g. TNF-α [119], and could 
lead to per oxidation of maternal plasma lipids during passage of maternal blood through 
the placenta and activation of maternal neutrophils; all of which could contribute to 
maternal endothelial cell activation. Recent invitro evidence has also suggested that the 
high concentrations of plasma endothelin-1 (ET-1) in women with pre-eclampsia could 
act as a trigger for oxidative stress in the placenta [120]. Oxidative stress was shown after 
invitro exposure to ET-1 in normal placental explants by increased levels of 
malondialdehyde (MDA), a marker of lipid peroxidation, and lowered expression of 
antioxidant defense molecules including glutathione and ascorbic acid. Another likely 
source of oxidative stress is increased superoxide generation, through activation of the 
enzyme NADPH oxidase; an increase in activity of this enzyme has been shown in 
placental tissue from women with early compared to late onset pre-eclampsia as assessed 
using luminometry (with lucigenin) to detect superoxide generation, and by employing 
pharmacological inhibitors of NADPH oxidase to delineate the contribution from the 
enzyme [121]. Others have shown upregulation of NADPH oxidase using 
immunohistochemical methods [122]. Angiotensin is a potent agonist of NADPH oxidase 
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and it has been proposed that NADPH oxidase activation could occur through synthesis 
of a stimulating antibody to the angiotensin receptor, which has been described by several 
groups in the plasma of women with pre-eclampsia [123]. In view of this literature they 
proposed that antioxidants might be effective in prevention of preeclampsia. They 
undertook a randomized placebo controlled trial of vitamin C (1 gm/day) and vitamin E 
(400 IU/day) in 2404 women at risk of pre-eclampsia on the basis of their clinical history. 
However, the incidence of pre-eclampsia was the same in both arms of the study [124], 
an observation repeated in another study from Australia in 2000 low risk women [125]. It 
is hoped that ongoing studies using a large biobank of plasma samples from participating 
women in the high-risk study will shed some light on the reasons why antioxidant, why p 
rophylaxis was in effective. 
1.14.4 Total antioxidant capacity: 
Pregnancy is a physiological process, yet many diseases occur for the first time during 
pregnancy because of oxidative stress [126]. Pregnancy therefore tends to promote 
oxidative stress [127], as markers of oxidative stress are known to be raised in normal 
pregnancy [128]. Total antioxidant capacity represents the balance between oxidative 
stress (oxidants) and the neutralizing systems (antioxidants). The oxidants are mainly 
reactive oxygen species and their derivatives e.g. peroxynitrite anion, [129]. In contrast, 
homeostasis against the effects of reactive oxygen species and their derivatives is 
maintained by antioxidants such as catalase, super oxide dismutase, beta-carotene, 
vitamin C, vitamin E, glutathione peroxides, ceruloplasmin and transferin. These agents 
intercept, modify or destroy the reactive free radicals [130]. Antioxidants therefore 
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mitigate oxidative stress in pregnancy. Total antioxidant capacity is a measure of the 
neutralizing effects of antioxidants.  
            Problems arise when there is an imbalance between the prooxidants and 
antioxidants either because of excessive generation of pro-oxidants or because of reduced 
levels of the antioxidant systems, leading to inadequate reducing capacity of the 
antioxidants [131]. The consequence of this, is an increased plasma levels of pro-oxidant 
free radicals (e.g. hydroxyl radical (HO¯), superoxide anion radical (O2−), nitric oxide 
(NO), hydrogen perioxide (H2O2), hypochlorous acid (HOCl) and peroxynitrite anion 
(ONOO). These free radicals attack polyunsaturated fatty acids or cholesterol in 
membranes or lipoproteins (lipid hydroperoxidation). Lipid hydroperoxides function in 
normal physiology by regulating enzymes and redox sensitive genes [132], However this 
necessary physiology in normal pregnancy can become pathologic if lipid peroxidation 
becomes uncontrolled resulting in cellular dysfunction and damage and increase in 
vascular resistance, as in preeclampsia [133].  
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1.14.5 Body antioxidant defense mechanisms: 
1. Antioxidant enzymes 
2. Antioxidant vitamins 
      3. Other antioxidants 
1.14.5.1 Antioxidant enzymes: 
1.14.5.1.1 Glutathione peroxidase:  
 
Figure (1-1) reaction catalyzed by glutathione peroxidase  
Glutathione peroxidase is a selenoenzyme responsible for elimination of reactive oxygen 
species. It requires two molecules of reduced glutathione to break hydroperoxides. It’s an 
important part of the antioxidant defense system. Today five isoforms are known; 
therefore it is called more like an enzyme family than a single enzyme. They are present 
in almost every cell of animals, but the tissue distribution of the isoforms shows high 
variation. There are several factors abrogating the activity of the enzyme. Some of these 
are internal, individual factors, resulting in significant variation in the enzyme activity of 
different organs, age groups and sex. Endocrine regulation can also control enzyme 
activity. However, environmental factors have also definite effect on enzyme action. 
Nutrition is one of the most essential factors as fat content and fatty acid composition of 
feed, or trace element intake as well as vitamin status of the animal play crucial role in 
normal enzyme activity. In addition to GPX1, there are five other known GPX enzymes: 
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GPX2–GPX6. Data from invitro activity assays suggest that all members use GSH to 
catalyze the reduction of hydrogen peroxide and lipid peroxides. Whereas GPX1 is the 
most abundant selenoperoxidase and is ubiquitously expressed in almost all tissues [134-
137], GPX2 expression is most prominent in the gastrointestinal tract [138]. Expression 
of GPX3 is greatest in the kidney, although this enzyme is expressed in various tissues 
and is secreted into extracellular fluids as a glycoprotein [139, 140]. Different from other 
glutathione peroxidases, GPX4, or phospholipid hydroperoxide GPX, is not a tetramer, 
but rather a monomer, and is the only GPX enzyme that reduces phospholipid 
hydroperoxides [141]. In addition, GPX4 contains a mitochondrial isoform that mediates 
the apoptotic response to oxidative stress [142, 143], and has a peroxidase independent 
structural role after sperm maturation [144]. Recently, GPX6 was identified as a 
selenoprotein in the human genome by homology search. However, GPX6 from rodents 
and GPX5 from both humans and rodents do not contain Selenocysteine or Selenium 
[145]. 
1.14.5.1.2 Glutathione peroxidase in preeclampsia: 
Glutathione levels and glutathione peroxidase enzyme activity were found to be higher in 
women with pre-eclampsia. [146].  Glutathione peroxidase, an enzyme that removes 
hydrogen peroxide and converts lipid hydroperoxides to less reactive alcohols, may be 
deficient in placental tissue from preeclamptic women. This is seen in conjunction with 
increased in vitro placental production of lipid hydroperoxides and thromboxane A2 
(TXA2) [147]. TXA2 is a vasoconstrictive and pro-aggregatory prostaglandin normally 
counter regulated by prostacyclin (PGI2). Chemical inhibition of placental glutathione 
peroxidase resulted in increased production of lipid hydroperoxides and an increase in the 
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placental TXA2 to PGI2 output ratio [148]. Lipid hydroperoxides can inhibit PGI2 
synthase enzyme activity and simultaneously stimulate the cyclooxygenase component of 
PGH synthase [149] whereas TXA2 synthase activity is unchanged or even stimulated. 
Since expression of the synthases is not altered in the uteroplacental unit [150], these 
effects of lipid hydroperoxides could be the source of the decreased placental PGI2 to 
TXA2 production ratio in preeclampsia. The altered prostaglandin ratio might provoke 
vasospasm with exacerbation of placental ischemia, increased cell damage, and increased 
lipid peroxidation (amplification of oxidative stress) [151].  
1.14.5.1.3 Superoxide dismutase: 
 
Figure (1-2) reaction catalyzed by superoxide dismutase 
Superoxide Dismutase (SOD) catalyzes the reduction of superoxide anions to hydrogen 
peroxide; it’s present in virtually all cell types. It plays a critical role in the defence of 
cells against the toxic effects of oxygen radicals. SOD competes with nitric oxide (NO) 
for superoxide anion, which inactivates NO to form peroxynitrite. Therefore, by 
scavenging superoxide anions, SOD promotes the activity of NO. 
The action of superoxide is normally limited by its low lipid solubility, its limited 
membrane transport, and also by its removal by SOD. SOD exists in several isoforms, 
including the cellular copper/zinc (cytosolic, 32 kD) and the manganese (mitochondrial, 
80 kD) isoforms [152], and an extracellular isoform [153]. These isoforms show no 
sequence homology with each other. SOD activity has been described in the human 
placenta, and normally placental lipid peroxides decrease but SOD activity increases 
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throughout gestation [154, 155], presumably to prevent excessive superoxide 
accumulation and consequential deleterious effects in the placenta. In placentas of pre-
eclamptic pregnancies, increased levels of lipid peroxides are seen [81], and decreased 
SOD activity has been described in patients with pregnancy-induced hypertension [156]. 
This decreased activity of SOD in pregnancy-induced hypertension may be associated 
with increased superoxide production and lipid peroxidation. 
1.14.1.5.4 Catalase: is a common enzyme found in nearly all living organisms. Its 
functions include catalyzing the decomposition of hydrogen peroxide to water and 
oxygen. Catalase has one of the highest turnover rates of all enzymes; one molecule of 
catalase can convert millions of molecules of hydrogen peroxide to water and oxygen per 
second. Catalase is a tetramer of four polypeptide chains; each over 500 amino acids 
long.It contains four porphyrin heme (iron) groups that allow the enzyme to react with 
the hydrogen peroxide. The optimum pH for catalase is approximately 7, while the 
optimum temperature varies by species. 
 
Figure (1-3) reaction catalyzed by catalase 
 
 
 
 48
1.14.5.2 Non-enzymatic antioxidants: 
The non-enzymatic antioxidant defense system includes ascorbic acid (vitamin C), α-
tocopherol (vitamin E), glutathione (GSH) and β-carotene (total antioxidant status). There 
is a balance between both the activity and intracellular levels of these antioxidants that 
are essential for the survival of organisms and their health [157-160]. 
1.14.5.2.1 Antioxidants vitamins: 
It has been suggested that deficiency in antioxidant vitamins would be associated with the 
development of pre-eclampsia [161, 162]. Antioxidant vitamins have been reported to 
have an important function in regulating blood pressure [163]. Nitrous oxide (NO) is the 
most important endothelium dependent vasodilator and is highly susceptible to oxidative 
damage. The antioxidant vitamins C and E are able to inhibit formation of free radicals 
thereby inhibiting the oxidation of NO, and thus maintain the vasodilator status of blood 
vessels. Damage From free radicals has been implicated in many pathological conditions. 
It is believed that increased free radical activity arises from increased production of free 
radicals or deficiency in protective antioxidant systems(including antioxidant vitamins; 
vitamin A, E, C, and Beta-carotene) , which may lead to endothelial dysfunction in 
pregnancy induced hypertension(PIH) [164]. The unsaturated lipids and thiol containing 
proteins in cell membranes are susceptible to free radical attack. There are reports about 
increased free radical activity in PIH [165].But little is known about the part played by 
changes in specific antioxidants. Several lines of evidence indicate that adverse changes 
in structure and function of maternal vascular endothelium accounts for the vascular 
activity, activation of coagulation cascade and multi system damage in preeclampsia. 
Multiple circulating factors may provoke the spectrum of endothelial changes, including 
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lipoproteins [166].  Placental hypoxia or ischemia could result in release of products into 
maternal circulation which then initiates the maternal pathological changes. Lipid 
peroxidation products are candidate factors that may mediate disturbances of other 
maternal vascular endothelium.  
1.14.5.2.1.1 Vitamin E: 
The term vitamin E covers 8 different forms that are produced by plants alone: α-, β-, γ-, 
and δ- tocopherol and α -, β -, γ -, and δ -tocotrienol [167].  The mechanism of vitamin E 
absorption is surprisingly unclear. All forms of vitamin E are taken up by intestinal cells 
and released into the circulation with chylomicrons.  At this step there is probably no 
discrimination between the different forms.  
The vitamins reach the liver via chylomicron remnants. In the liver, a specific protein, α-
tocopherol transport protein (α –TTP), selectively sorts out α -tocopherol from all 
incoming tocopherols for incorporation into VLDL. The concentration of α-tocopherol in 
normal subjects is about 25µmol/L. 
Vitamin E is a lipid soluble and chain breaking antioxidant. Vitamin E acts in vivo to 
prevent the formation of lipid peroxides and thus protect cell membranes. It scavenges 
radicals in membranes and lipoprotein particles and is central to the prevention of lipid 
peroxidation. In lipoproteins and cell membranes vitamin E traps peroxyl radicals, 
breaking the chain reaction of lipid peroxidation by minimizing the formation of 
secondary radicals [168]. 
 Several studies found lower plasma Vitamin E in patients with PIH [169]. Ascorbate is 
the water soluble antioxidant vitamin, reacts rapidly with superoxide and peroxyl radicals 
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and even more rapidly with hydroxyl radicals to give semidehydroascorbate. Furthermore 
deficiency of Vitamin C causes impaired immune responses [170].  
1.14.5.2.1.1.1 Vitamin E in human pregnancy: 
 
During pregnancy, the blood α-tocopherol concentration increases in association with the 
increase in blood lipid concentration [171]. In abnormal pregnancies, blood α-tocopherol 
concentrations are lower than those in normal pregnancies at a corresponding gestational 
age [172]. It is assumed, though unproven, that vitamin E requirements increase during 
pregnancy. For this reason, vitamin supplements designed for pregnancy usually contain 
small doses (50 mg) of vitamin E, but adverse effects have not been observed with higher 
levels of supplementation. It is well established that there is no clear relation between 
maternal and fetal blood concentrations of vitamin E. Newborns have significantly lower 
plasma vitamin E concentrations than do their mothers [173].  
However, when plasma vitamin E concentrations were standardized for phospholipids or 
total lipids, significant differences were not seen [174, 175]. Short-term supplementation 
of pregnant women before delivery significantly enhanced the vitamin E status of the 
mother only [176], suggesting that vitamin E does not pass efficiently through the 
placenta to the newborn circulation. What regulates the placental transfer remains 
unclear.  
1.14.5.2.1.1.2 Vitamin E in preeclampsia: 
 
Researchers investigating the role of vitamin E in the prevention of preeclampsia have 
focused on its antioxidants properties. In two studies in which the effect of vitamin E 
supplementation on women with established preeclampsia was examined, no benefit was 
observed [177, 178]. Importantly, however, the early provision of antioxidants like 
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vitamins E and C to women at high risk of developing preeclampsia has a marked clinical 
benefit. On the basis of an abnormal uterine artery as determined with 2-stage Doppler 
analysis or of a previous history of preeclampsia, Chappell et al. 1999 [179] identified 
283 women who were at an increased risk of preeclampsia. The subjects who were 
supplemented with vitamins E (263 mg/d) and C (1000 mg/d) had an 8% incidence of 
preeclampsia, whereas those who received placebo had a 17% incidence of the disorder. 
Interestingly, vitamin usage was associated with better endothelial function and less 
placental dysfunction. These findings, along with the decreased concentrations of 
isoprostanes in the women who received vitamin supplements, provide a sound 
biochemical basis for understanding the improved clinical symptoms. 
1.14.5.2.1.2 Vitamin A: 
The term  retinoids  introduced in 1976 includes carotenoids, the natural forms of vitamin 
A as synthetic analogues, retinol, the vitamin A alcohol (which is derived from animal 
sources), retinal and retinoic acid, which are the main vitamin A active metabolites.  
The recommended adult intake of vitamin A (retinol), commonly found in liver, eggs, 
oily fish, fortified margarine, and dairy products, is 3000 to 5000 IU daily. Hepatotoxic 
effects, vision changes, hair and skin changes, and teratogenic effects can occur with 
intakes greater than 10,000 IU [180]. 
When taken orally, the body can absorb vitamin A much better than β-carotene. The 
bioavailability and conversion of β-carotene to vitamin A itself is very variable, being 
dependent on the dietary content of fat, bile salt concentration and the level of other 
vitamins in the body.  β-carotene does not combine with specific carrier proteins and does 
not require receptors to perform its provitamin actions. Vitamin A, however, requires a 
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specific carrier serum protein (retinol-binding protein, RBP) and specific cellular 
receptors to perform its actions. Clinical and sub clinical infection as well as malnutrition 
affect RBP and receptor levels. Unlike β-carotene, vitamin A is highly toxic when taken 
in high doses and there is concern about its teratogenicity, although the level that could 
produce this in humans is still ill defined [181]. High doses of vitamin A are toxic 
because the body lacks efficient mechanisms to excrete or destroy excessive loads of it, 
this could cause catastrophic effects, particularly on cell membranes and possibly on the 
genome [182]. The antioxidant effect of vitamin A is largely attributed to β-carotene and 
other carotenoids. Therefore, while β-carotene can perform all the actions of vitamin A, 
the reverse is not true. 
1.14.5.2.1.2.1 Vitamin A in pregnancy: 
Placental development depends on a complex and incompletely understood interaction 
between foetal and maternal cells. Highly specific receptors for retinol binding protein –
RBP- (essential for the action of retinol) are expressed in the human placenta [183]. The 
level of RBP in the placenta is higher than in any other tissue of the body, including the 
retina [184]. Placental β-carotene level is almost twice as great as those found in the liver 
[185]. The presence of these high and specific levels of both vitamin A and its precursors 
suggest that vitamin A is essential for the placenta, or foetus, or both. It is conceivable 
that vitamin A deficiency could lead to problems of implantation and placental 
development, which in turn could lead to problems of placental separation and 
postpartum or post-abortion haemorrhage, or placenta praevia and placental abruption. 
Indeed, Sharma et al 1986 [186] reported significantly lower levels in serum vitamin A 
and β-carotene when comparing cases with abruptio placentae to controls.  However, 
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vitamin A deficiency may be the cause or effect of the abruption as a decrease in vitamin 
A can be part of an acute phase response and decreased β-carotene may be the result of 
increased consumption as an antioxidant to combat the oxidative stress of placental 
abruption. Other causes of obstetric haemorrhage include coagulopathy. Normal 
coagulation depends on the adequate function of platelets, healthy endothelium and 
harmony between coagulation factors. Vitamin A seems to have no effect on platelet 
aggregation and adhesion [187, 188]. Endothelium injury is the starting point that triggers 
abnormal aggregation of the coagulation factors and leads to coagulopathy. Vitamin A 
appears to increase the integrity and vitality of endothelial cells [189] and so could 
possibly prevent endothelial injury.  After endothelium injury, coagulation factors start to 
accumulate, forming abnormal small clots that initiate a vicious cycle of disseminated 
intravascular coagulopathy. The increased consumption of coagulation factors leads to its 
exhaustion and profound haemorrhage. Vitamin A supplementation may have an effect 
on the clotting system through increasing thrombomodulin [190,191] decreasing 
antithrombin III [192] and increasing tissue plasminogen activator [193, 194]. This, 
together with the endothelial protective effect, suggests that vitamin A may be capable of 
preventing coagulopathy from the beginning or decrease its severity if it occurred. 
1.14.5.2.1.2.2 Vitamin A and infection in pregnancy or the post-abortion or 
postpartum period: 
Pregnancy-related infection (PRI) may result from colonization of retained products of 
conception (usually a part of the placenta), pre-existing infection or from non sterile 
invasive procedures. PRI has rarely been associated with vitamin A deficiency. 
 In the Vanderbilt cooperative study of infant and maternal nutrition of 1945, women who 
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experienced puerperal infection were found to have lower vitamin A levels starting from 
the second trimester and continuing through the postpartum examination [195]. 
Bacteriuria (suggestive of urinary tract infection) was observed in 80% of pregnant 
women presenting with clinical vitamin A deficiency [196]. Cases with vaginal 
candidasis showed a significant decrease in β-carotene concentration in exfoliated vaginal 
epithelial cells when compared to controls [197]. Pregnant women with night blindness 
were also twice as likely to have clinical genitourinary tract infections (lower abdominal 
pain, painful micturition or vaginal discharge) than controls without night blindness 
[198]. The relationship between infection and decreased vitamin A levels is, however, not 
that simple. Night-blind women in the study mentioned above were also more likely to be 
anaemic, undernourished, of lower cast and illiterate which could explain an element of 
the association [198].The decreased vitamin A levels found in infection might be due to 
decreased absorption of dietary vitamin A (due to diarrhoea or the activity of intestinal 
pathogen) [199], decreased RBP production, [200] or increased loss of vitamin A in urine 
[201, 202].  In acute phase reaction, there is a transient decrease in the production of 
small molecular weight proteins, including RBP, and an increase in the permeability of 
renal epithelial cells. Decreased vitamin A might also be due to increased uptake of 
retinol by certain tissues [203]. PRI could be reduced through three main pathways: 
promotion of wound healing; increased resistance to infection; and immune enhancement 
if infection occurs. Vitamin A increases the production of TGF-b, which is involved in 
the promotion of wound healing [204], and decreases fibrosis through suppression of the 
fibroblasts. These two actions may increase the integrity of the mucosal surfaces of 
genitourinary tracts and promote better healing of episiotomy and perineal laceration, 
 55
thereby decreasing the chance of infection. Vitamin A augments natural resistance 
through increasing the naturally present antibodies, IgA, and promoting the function of 
neutrophils. Neutrophils are an important part of the first line of defense against infection 
as they engulf bacteria, viruses, parasites and virally infected cells. An alteration in all the 
components of neutrophil function has been demonstrated in vitamin A-deficient rats 
[205]. The progress of infection depends on three factors: (i) the virulence and dose of the 
pathogen; (ii) host immunity; and (iii) the usage of appropriate antimicrobial agents. It is 
unlikely that either vitamin A deficiency or supplementation could alter the pathogen but 
the expected effect will be brought about through enhancing different components of the 
immune system. Vitamin A helps the control of viral infection. Retinoids regulate cell 
growth and differentiation as well as apoptosis (programmed cell death seen in viral 
infection and tumour cells) [206]. Both the number and the activity of NK cells (which 
are involved in antiviral and antitumour immunity) are decreased in vitamin A deficiency 
[207]. Supplementation of vitamin A results in an increase of NK cells in children with 
acquired immunodeficiency syndrome (AIDS) [208]. The successful production of 
antibodies to compete with the bacteria depends on three types of cells: (i) antigen 
presenting cells (APC), which present the bacterial antigen to the immune-specific cells 
(lymphocytes); (ii) B lymphocytes, which are responsible for antibody production; and 
(iii) T lymphocytes, which regulate the immune response. 
Retinol is required for growth and activation of B lymphocytes in humans [209, 210]. 
Transretinoic acid augments the production of two types of antibodies: IgM (antibody of 
the first immune response) and IgG (antibody of the secondary immune response) [211]. 
Retinol seems to be required for the activation of T lymphocytes [212]. In vitamin A 
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deficiency, antibody response is impaired for both T-cell dependent antigen [213] and T-
cell-independent antigen [214]. Vitamin A may decrease the incidence and severity of 
RPI by promoting wound healing, increasing resistance to infection and immune 
enhancement if infection occurs. 
1.14.5.2.1.2.3 Vitamin A and hypertensive disorders of pregnancy: 
Many observational studies found a significant decrease in vitamin A and β-carotene in 
pre-eclamptic women when compared with normal pregnant women. This decrease was 
found both in serum [215-218], as well as amniotic fluid [219]. The constant association 
between decreased retinol and β-carotene levels with pre-eclampsia, however, does not 
prove a causal relationship. Decreased retinol might be a part of an acute phase reaction. 
Many studies found decreased serum proteins in toxaemia of pregnancy [215, 220, 221] 
and retinol is carried on proteins, thus its decrease could be secondary to decreased 
protein levels. Other studies correlated pre-eclampsia and eclampsia with increased 
oxygen free radicals [222] and decreased antioxidant activity [223-227]. Thus, the 
decreased β-carotene might be due to increased consumption as it is an antioxidant. These 
observational studies are supported by an in vitro study that showed that β-carotene levels 
present in normal pregnant women significantly inhibited peroxide-induced 
vasoconstriction in a dose-dependent manner.  
Lower levels of β-carotene, like those present in pre-eclampsia, were not able to achieve 
the same effect [228]. A recent nested case-control study from Nepal compared 109 
pregnant women with impending night blindness (xerophthalmia, XP) (cases) and 
without XP (controls). Plasma levels of retinol (but not β-carotene) were significantly 
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decreased (P,0.001) while rates of pre-eclampsia/eclampsia were significantly increased 
in patients with imminent XP [198]. 
   The effect on pre-eclampsia/eclampsia was not observed after XP had developed. 
Endothelial cell dysfunction is the common pathway in the pathogenesis of pre-
eclampsia. β-carotene is a recognized antioxidant and free radical scavenger, and this 
beneficial effect is related to its provitamin activity. β-carotene and other carotenoids are 
much more effective antioxidants than vitamin A. Nitric oxide is a potent vasodilator 
substance that is believed to play a major role in increasing placental perfusion [229]. 
Oxidation of low density lipoprotein (LDL) decreases the release of nitric oxide. β-
carotene is carried on LDL and protects it against oxidation and thus promotes nitric 
oxide vasodilatation. This effect has been demonstrated in animals [230], invitro [231] 
and in humans [232]. A randomized, double-blind placebo controlled trial of vitamins E 
and C (stronger antioxidants than β-carotene) supplementation in women at increased risk 
of pre-eclampsia showed a marked reduction in preeclampsia in the intervention group 
(adjusted odds ratio 0.39 [0.17±0.90]) [179]. The underlying pathology in pre-eclampsia 
appears to be insufficient placental implantation. This is thought to lead to a relatively 
hypoxic maternal-foetal interface, an increased turnover of trophoblast tissue, higher 
xanthine and hypoxanthine concentrations and higher levels of circulating cytokines and 
an increased production of uric acid and free radicals [233]. It is unlikely that β-carotene 
or other antioxidants can totally correct these multiple abnormalities. In established 
severe cases it is unlikely to restore normality except by delivery. 
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1.14.5.6 Omega-3 and omega-6 unsaturated fatty acids: 
Some of the polyunsaturated fatty acids (PUFAs), omega-6 and omega-3 fatty acids, are 
called essential fatty acids because the body cannot synthesize them. Their contribution is 
19% to 22% of energy intake from fats in the western diet. The rest is saturated and 
monosaturated fat [234].  PUFAs can be confusing because of the similarity of some of 
the names and the variety of names that refer to the same fatty acid. Omega-6 and omega-
3 fatty acids are also called n-6 and n- 3 fatty acids. These names refer to the chemical 
structures [235].  
Figure (1-4) chemical structure of EPA 
 
 
Figure (1-5) chemical structure of DHA 
 
 
Figure (1-6) chemical structure of arachidonic acid 
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 PUFAs are hydrocarbon chains with a methyl group at one end (called the omega end) 
and a carboxyl group at the other. “Omega-6” refers to the first double bond that occurs 
at the sixth carbon from the omega (methyl) end. It’s also noted as C18:2 omega-6 or 
C18:2n-6 (18 carbons, 2 double bonds with the first at the n-6 position) [235].  Omega-3 
fatty acids have a double bond at the third carbon (n-3). Alpha-linolenic is an example of 
a short chain omega-3 fatty acid. Alpha linolenic acid is also called simply linolenic acid.  
Αlpha-linoleic acid and gamma-linolenic acid are omega-6 fatty acids. It’s sometimes 
written as C18:3 omega-3 or C18:3n-3; 18 carbons, 3 double bonds with the first at the n-
3 position [235].   Long chain omega-3 fatty acids include eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). EPA is C20:5 omega-3 and DHA is C22:6 omega-3. 
Linoleic acid is the predominant dietary omega-6 fatty acid; 84% to 89% of dietary 
PUFAs come from linoleic acid in meats, grains, and the seeds of most plants. Linoleic 
acid is metabolized to arachidonic acid. Arachidonic acid is converted to inflammatory 
prostaglandins and leukotrienes, which have been linked to cardiovascular and other 
diseases [234, 235]. Alpha-linolenic acid contributes about 9% to 11% of PUFAs in the 
U.S. diet. It is sometimes called plant or vegetable omega-3. Vegetable oils such as soy 
and canola are the primary sources, but flaxseed, walnuts, and other nuts also contain 
significant amounts of alpha-linolenic acid. The body can convert small amounts of 
alpha-linolenic acid to EPA, and minute amounts to DHA. EPA and DHA are also called 
marine omega-3s because they are found in fish. Fatty fish such as mackerel, herring, 
salmon, tuna, lake trout and halibut contain the highest concentrations [234, 235]. Despite 
the epidemiologic evidence of benefit, randomized trials don’t support supplementation 
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with fish oil to prevent pre-eclampsia, pregnancy induced hypertension, low birth weight, 
or intrauterine growth retardation. DHA or fish oil may increase length of gestation by 
several days, and reduce risk of recurrent preterm delivery in singleton pregnancies. 
Studies show a correlation between newborn DHA levels and newborn brain maturity and 
infant visual maturation. But despite these findings, maternal fish oil supplementation 
during pregnancy has not been shown to affect infant cognitive function. Fish oil 
supplementation during pregnancy through the first three months of breast feeding may 
very slightly benefit intelligence at age four.  
Maternal supplementation with DHA during breastfeeding has also been shown to benefit 
psychomotor development at age 30 months. Some studies comparing DHA 
supplemented versus standard formula also suggest cognitive and visual benefits, 
particularly in preterm infants. Evidence from most cohort and case-control studies 
suggests omega-3s may protect against postpartum depression. 
Habitual consumption of modest amounts of fish and other sea food has been associated 
with a reduction in the risk of heart disease [236]. Results from controlled metabolic 
studies have provided strong evidence for the role of fish oil (i.e., long chain omega-3 
polyunsaturated fatty acids) played in reducing circulating triglycerides, decreasing 
platelet and leukocyte reactivity, attenuating imbalances between the potent eicosanoids 
such as prostacyclin and thromboxane in favor of vasodilatation, and reducing systolic 
and diastolic blood pressures [236, 237].  The beneficial effects of fish oil appear to be 
associated with the long chain polyunsaturated omega-3 fatty acids; eicosapentaenoic, 
docosapentaenoic and docosahexaenoic acids. Arachidonic acid, an omega- 6 fatty acid, 
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has been shown to have opposite effects of omega-3 fatty acids on circulating lipids, 
platelet and leukocyte reactivity, as well as eicosanoid biosynthesis [237, 238]. 
1.14.5.6.1 Omega-3 and omega-6 fatty acids in preeclampsia: 
Preeclampsia, one of the most common medical complications of pregnancy [239], is a 
leading cause of maternal mortality worldwide, as well as an important cause of 
premature delivery, fetal growth retardation, and perinatal mortality. Pregnancies 
complicated by preeclampsia are preceded by hyperlipidemia, particularly 
hypertriglyceridemia. Other pathologic changes associated with preeclampsia include 
maladaptation of spiral arteries of the placental bed, excessive lipid peroxidation, 
endothelial cell dysfunction, thromboxane/prostacyclin imbalance, elevations in 
proinflammatory cytokines, altered membrane fluidity, and elevations in plasma 
homocysteine concentrations [239-241].  
Controlled metabolic studies provided evidence suggesting that manipulation of the 
dietary intake of omega-3 fatty acids, omega-6 fatty acids, and trans fatty acids may 
prevent or ameliorate several of these pathophysiological processes [236, 242]. 
Investigators have previously shown that derangements in omega-3 and omega-6 fatty 
acids in plasma phospholipids or erythrocytes are associated with preeclampsia and other 
adverse pregnancy outcomes [243-246]. 
 
 
 
 
 
 
 
 
 
 
 62
 
GENERAL OBJECTIVES: 
The general aim of this study was to investigate the role of cytokines imbalance and 
oxidative stress in the pathogenesis of preeclampsia in patients attending Khartoum 
Teaching Hospital. 
SPECIFIC OBJECTIVES: 
A. cytokines and pathogenesis of preeclampsia 
1. To determine the levels of interferon gamma (IFN-γ), as Th1 cytokine and interleukin-
4 (IL-4), interleukin-10 (IL-10), as Th2 cytokines in sera of women with preeclampsia 
and the control group. 
2. To investigate the relationship of Th1/Th2 cytokines imbalance to the pathogenesis of 
preeclampsia. 
B. oxidative stress and pathogenesis of preeclampsia 
3. To determine the plasma levels of vitamin E (α-tocopherol) and vitamin A (retinol), in 
women with preeclampsia and the control group.  
4. To determine the activity levels of erythrocyte anti-oxidant enzymes; glutathione 
peroxidase, catalase and superoxide dismutase in women with preeclampsia and the 
control group. 
5. To determine the levels of red cell membrane omega-3, omega-6 fatty acids in three 
phospholipid fractions; phosphatidylcholine, phosphatidylethanolamine and 
sphyngomyelins in women with preeclampsia and the control group. 
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Chapter two 
 
Materials & methods 
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Materials and methods 
2.1 Study design: 
This is a case-control study conducted to study the role of cytokines imbalance and 
oxidative stress in the pathogenesis of preeclampsia in patients attending Khartoum 
Teaching Hospital.  
2.2 Study centre: 
Khartoum teaching hospital, Khartoum, Sudan 
2.3 Research ethics: 
Informed verbal consent was obtained from all patients and controls to participate in the 
study. 
The study was approved by the board of medical research of the Faculty of Medicine, 
University of Khartoum. 
2.4 Study population: 
1. Patients: 
A total number of 98 women with preeclampsia in the third trimester (33 for cytokines 
imbalance study, and 65 for evaluation of oxidative stress) were included in the study. 
2. Controls: 
A total number of 92 healthy pregnant women at the same gestational age as the patients 
in the third trimester (32 for cytokine study and 60 for study of oxidative stress) were 
included. 
The study was conducted in two phases; the first for cytokine profiles; namely interferon 
gamma (IFN-γ) interleukin-4 (IL-4) and interleukin-10 (1L-10), was carried during the 
period of March through July 2007. Patients with preeclampsia (n=33) were approached 
to participate in the study.  Volunteer women with normal pregnancy (n=32) at the same 
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gestational age were selected as a control group. Well- structured questionnaires were 
used to gather socio-demographic characteristics. Preeclampsia was diagnosed according 
to the criteria of the international society for the study of hypertension in pregnancy 
previously normotensive women with two repeat (4 h apart) diastolic blood pressure 
measurements of 90 mmHg or greater after the 20th week of gestation, plus proteinuria of 
more than 300 mg/l in 24 h as measured quantitatively or, >2+ protein by dipstick in two 
repeat measurements (4 h apart). Gestational age was calculated from the last menstrual 
period and confirmed by ultrasound in suspected cases.  
2.5 Sample collection for cytokines: 
Venous blood samples (5ml) were collected twice in plain tubes from 33 women with 
preeclampsia one at the time of hospital admission and seven days later during 
pregnancy, and once from 32 women with normal pregnancy at the same gestational age 
in the third trimester. The blood samples were centrifuged within 30 minutes from the 
time of collection at 2000 rpm, serum was aliquoted and stored at -20 degrees till the 
assay. All of these women were not in labour at presentations or seven days later. 
2.6 Data collection: 
Personal and clinical data were collected from patients and controls by a structured 
questionnaire 
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2.7 Cytokines measurement: 
ELISA kits (eBioscience) were used to determine the levels of three cytokines; interferon 
gamma (IFN-γ), interleukin-4 (IL-4) and iterleukin-10 (IL-10) in sera of preeclamptic 
women and women with normal pregnancy. All samples were run in duplicates and the 
mean value of optical density (OD) was calculated.   
2.7.1 Interferon gamma (IFN-γ):  sensitivity of the assay was 4 pg/ml. the standard 
 
curve range was 4- 500 pg/ml. 
 
2.6.1.1 Components: 
 
1. Capture Antibody: Pretitrated, purified antibody, clone NIB42 
2. Detection Antibody: Pretitrated, biotin conjugated antibody, clone 4S.B3 
3. Standard: Recombinant cytokine for generating standard curve and calibrating samples 
4. ELISA/ELISPOT Coating Buffer Powder: Reconstituted to 1L with dH20. 
5. Assay Diluent: 5X concentrated 
6. Detection enzyme: pretitrated Avidin-HRP 
7. Substrate Solution: Tetramethylbenzidine (TMB) Substrate Solution 
8. ELISA plates (96 Well Plates). 
2.7.1.2 Other materials needed:  
1. Wash Buffer: 1 x PBS, 0.05% Tween20 (or eBioscience ELISA Wash Buffer Powder, 
cat 00-0400) 
2. Stop Solution: 1M H3 PO4  or 2N H2SO4 
3. ELISA plate reader (micro plate spectrophotometer) 
4. ELISA plate washer 
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2.7.1.3 Storage: 
Cytokine standard was stored at -80°C; other reagents were stored at 4 °C. 
2.7.1.4 Experimental procedure:  (was the same for the three cytokines) 
1. The 96 well ELISA plate was coated with 100 µl/well of capture antibody in Coating 
Buffer. The plate was sealed and incubated overnight at 4°C. 
2.  Wells were aspirated and washed 5 times with >250 µl/well Wash Buffer. Allowing 
time for soaking (~ 1 minute) during each wash step increases the effectiveness of the 
washes. Plate was blotted on absorbent paper to remove any residual buffer. 
3.  1 part 5X concentrated Assay Diluent was diluted with 4 parts distilled water, 200 
µl/well of 1X Assay Diluent was then added and the plate was incubated at room 
temperature for 1 hour. 
4. Standards were diluted with 1X Assay Diluent, and 100 µl/well of standard was added 
to the appropriate wells. Two fold serial dilutions of the top standards were performed to 
make the standard curve, and then 100 µl/well of the samples were added to the 
appropriate wells. 5. The plate was sealed and incubated at room temperature for 2 hours 
(or overnight at 4°C for maximal sensitivity). 
6. Aspiration/wash was done as in step 2 (repeated for a total of 5 washes). 
7. 100 µl/well of detection antibody diluted in 1X Assay Diluent was added and the plate  
was sealed and incubated at room temperature for 1 hour. 
8. Aspiration/wash done as in step 2 (Repeated for a total of 5 washes). 
9.  100 µl/well of Avidin-HRP diluted in 1X Assay Diluent was added, the plate was 
sealed and incubated at room temperature for 30 minutes. 
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10. Aspiration and wash as in step 2 (in this wash step, the wells were soaked in Wash 
Buffer for 1 to 2 minutes prior to aspiration, repeated for a total of 7 washes). 
11. 100 µl/well of Substrate Solution was added to each well. The plate was incubated at 
room temperature for 15 minutes. 
12.  50 µl of Stop Solution was added to each well. 
13.  The plate was read at 450 nm with an ELISA reader, and the results for cytokines 
were printed in duplicates for each sample. 
2.7.2 Interleukin-4 (IL-4): 
Sensitivity of the assay was 2 pg/ml, and the standard curve range was 2 - 200 pg/ml. 
 
2.7.2.1 Components: 
 
1. Capture Antibody: Pre-titrated, purified antibody, clone 8D4-8 
2. Detection Antibody: Pre-titrated, biotin-conjugated antibody, clone MP4-25D2 
3. Standard: Recombinant cytokine for generating standard curve and calibrating samples 
4. ELISA/ELISPOT Coating Buffer Powder: Reconstituted to 1L with distilled water. 
5. Assay Diluent: 5X concentrated 
6. Detection enzyme: pre-titrated Avidin-HRP 
7. Substrate Solution: Tetramethylbenzidine (TMB) Substrate Solution 
8. ELISA plates (96 Well Plate). 
2.7.2.2 Other materials needed: 
1. Wash Buffer: 1 x PBS, 0.05% Tween-20 (or eBioscience ELISA Wash Buffer Powder, 
cat 00-0400) 
2. Stop Solution: 1M H3PO4 or 2N H2SO4 
3. ELISA plates (96-well plate). 
4.  ELISA plate reader (microplate spectrophotometer) 
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5. ELISA plate washer. 
2.7.2.3 Storage:  
Cytokine standard was stored at -80°C; other reagents were stored at 4°C. 
2.7.3 Interleukin-10: 
The sensitivity of the assay was 2 pg/ml, the standard curve range was 2- 300 pg/ml 
 
2.7.3.1 Components: 
1. Capture Antibody: Pretitrated, purified antibody, clones NIB42, MQ117H12, 8D48, 
JES39D7 
2. Detection Antibody: Pretitrated, biotin conjugated antibody, clones 4S.B3, Rabbit 
Polyclonal Antibody, MP425D2, JES312G8 
3. Standard: Recombinant cytokine for generating standard curve and calibrating samples 
4. ELISA/ELISPOT Coating Buffer Powder: Reconstituted to 1L with dH20 and filter 
(0.22 uM). 
5. Assay Diluent: 5X concentrated 
6. Detection enzyme: pretitrated AvidinHRP 
7. Substrate Solution: Tetramethylbenzidine (TMB) Substrate Solution 
8. 96 Well Plate 
2.8 Oxidative stress: 
The second phase was carried out during the period of March -June 2008 in Khartoum 
teaching hospital, to study the role of oxidative stress in the pathogenesis of 
preeclampsia, which was assessed by unsaturated fatty acid profile in three fractions of 
red cell membrane phospholipids, namely; phosphatidyl ethanolamine, phosphatidyl 
choline and  sphyngomyelins, the level of plasma antioxidant vitamins, retinol and α-
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tocopherol and three erythrocyte antioxidant enzymes, glutathione peroxidase, catalase 
and superoxide dismutase. After an informed consent 65 pregnant women in their third 
trimester with preeclampsia were approached to participate in the study. A well matched 
(for age, parity and gestational age) 60 women with normal pregnancy were selected as 
the controls. Cases were further divided into mild and severe preeclampsia according to 
the diastolic blood pressure of < 110, or ≥110 mmHg respectively. Those women with 
multiple pregnancies, medical disorders including; diabetes mellitus or inflammatory 
conditions were excluded.  
2.8.1 Sample collection: 
Venous blood samples (5ml) were collected from both groups into tubes containing 
EDTA, covered from direct light. Samples were transported to the lab in the department 
of biochemistry, Faculty of Medicine, Khartoum University in containers with ice bags, 
where they were centrifuged with in half an hour after collection at 3000 rpm. Plasma 
was separated and red blood cells were washed three times with 0.9% NaCL, both were 
flushed with oxygen free nitrogen and stored at -80 °C until analysis in London 
metropolitan University, Institute of brain chemistry and human nutrition (IBCHN). 
Erythrocyte glutathione peroxidase, catalase and superoxide dismutase were measured 
with ELISA, fatty acid profile with gas chromatography and plasma retinol and α-
tocopherol with high performance liquid chromatography (HPLC). 
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2.8.2 Erythrocyte antioxidant enzymes: 
2.8.2.1. Sample preparation: 
A. Red blood cell lysate: 
To 100µL of red blood cells 400µL of ice cold HPLC grade water was added, this was 
then centrifuged at 10,000 X g for 15 minutes at 4°C. The supernatant was then collected 
into another tube and stored at -80 °C. All samples were assayed within the same week. 
2.8.2.1.1 Sample dilution: 1:500 for catalase and super oxide dismutase, and 1:50 for 
glutathione peroxidase assay. 
2.8.2.1.2 Enzymatic activity of red blood cell enzymes super oxide dismutase, catalase 
and glutathione peroxidase were assayed by   
ELISA kit (cayman chemical company U.S.A). 
2.8.2.2. Assay range and precision: 
A. For glutathione peroxidase: 
The dynamic range of the assay is limited only by the accuracy of absorbance 
measurement. Most plate readers are linear to the absorbance of 1.2. Samples cotaining 
GPx activity between 50-344 nmol/min/ml can be assayed without further dilution or 
concentration. When a series of seventy-seven GPx measurement were performed on the 
same day, the intra assay coefficient of variation was 5.7% and 7.2% as interassay 
coefficient of variation on five different days 
B. For catalase: 
The dynamic range of the assay is limited by the accuracy of the absorbance 
measurements. Most plate readers are linear to the absorbance of 1.2. Samples containing 
 72
catalase activity between 0.25-4 nmol/min/ml can be assayed without further dilution or 
concentration. 
When a series of 45 catalase measurements were performed on the same day, the intra 
assay coefficient of variation was 3.8%. When performed on five different days under the 
same experimental conditions, the inter assay coefficient of variation was 9.9%. 
C. For super oxide dismutase : 
Under standard conditions of the assay, the dynamic range of the kit is 0.025-0.25 
units/ml SOD. When a series of 60 SOD standard measurements were performed on the 
same day, the intra assay coefficient of variation was 3.2%. When performed on five 
different days under the same experimental conditions, the inter assay coefficient of 
variation was 3.7%. 
2.8.2.3 Assay reagents: 
1. Glutathione peroxidase: 
1. Assay buffer (10 X): 50mM Tris-HCL, pH 7.6, containing 5 mM EDTA. 
 2.  Sample buffer (10X): 50 mM Tris-HCL, pH 7.6, containing 5 mM 
EDTA and 1 mg/ml BSA. 
2. Glutathione peroxidase control: 
Solution of bovine glutathione peroxidase, it causes a decrease of 0.05 absorbance 
unit/min under the standard assay conditions. 
4. Glutathione co substrate mixture: 
Is a powder of NADPH, glutathione, and glutathione reductase. 
5. Glutathione cumene hydroperoxide: 
Is a solution of cumene hydroperoxide. 
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2. Catalase:  
1. Assay buffer: 100 mM potassium phosphate, pH 7.0 
2. Sample buffer: 25 mM potassium phosphate, pH 7.5, containing 1 mM   
EDTA and 0.1% BSA. 
3. Formaldehyde standard: contains 4.25 M formaldehyde. 
4. Catalase control:  contain powder of bovine liver catalase. 
5. Potassium hydroxide: contain potassium hydroxide pellets. 
6. Methanol 
7. Hydrogen peroxide: contain 8.8 M solution of hydrogen peroxide 
8. Purpald (chromogen): contains a solution of 4-amino-3-hydrazino-5-mercapto-1,2,4-
triazole (purpald) in 0.5 M hydrochloric acid. 
9. Potassium periodate: contains a solution of potassium periodate in 0.5 M potassium 
hydroxide. 
3. Super oxide dismutase: 
1. Assay buffer (10 X):  
50 mM Tris-HCL, PH 8.0, containing 0.1mM diethylenetriaminepentaacetic acid (DTPA) 
and 0.1 mM hypoxanthine. 
2. Sample buffer (10X): 
50 mM Tris-HCL, PH8.0. 
3. Super oxide dismutase assay radical detector: 
Contain a solution of tetrazolium salt. 
4. Super oxide dismutase standard: 
Contain a solution of bovine erythrocyte super oxide dismutase (Cu/Zn). 
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5. Super oxide assay xanthine oxidase: 
Contain a solution of xanthine oxidase 
ELISA reader with selection of the appropriate filter (340 (GPX),450 (CAT), 450 (SOD) 
was used to determine the absorbance for each. The actvity of each enzyme was then 
calculated by a specific equation.  
2.8.3 Fatty acid analysis 
 
 Stages of analysis of fatty acids: 
 
1. Chemistry: 
     Extraction, thin layer chromatography and methylation. 
2. Gas chromatography: 
      Running samples on the GC and collecting the data. 
3. Analysis: 
      Processing the raw chromatography (get peak retention times, identify peaks, get 
areas and area percentages). 
4. Interpretation: 
      Looking at the computer reports critically to ensure that the results are accurate and 
realistic. 
A. Extraction of RBC: 1 ml RBC was transferred into 15 ml methanol + BHT 
            (Butylated hydroxy toluene) in a 100 ml extraction tube and shacked to suspend 
theRBC and prevent clumping. 30 ml chloroform + BHT was added and shacked. 
Flushed with oxygen free nitrogen (OFN), and Stored at 4 °C for 24 hours. The 
nitrogen nozzle was cleaned with chloroform or C/M between samples. 
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B. Partitioning: 
1.  Samples were filtered into separating funnel. 
2. Extraction vessels were washed with 1 x 10 ml and 1 x 5 ml C/M (2+1 plus BHT) and 
each rinse was used to wash the filter paper. 
3. Filter funnels were removed and 25% v/v of 0.85% saline was added                                                          
(i.e. when using 45 + 10 + 5 ml = 60 ml C/M, add 60 / 4 ml = 15 ml saline). 
4. Flushing with caps on for about 1 min by bubbling OFN through the liquids was done, 
the samples were then Stored at 4 °C overnight. 
Rotatory evaporation: 
1.  The separating funnels were allowed to stand at room temperature for 30 minutes 
(this stops condensation). 
2.  The lower organic layer was drained into a 100 ml or 250 ml round-bottomed flask. 
3. The solvent was removed under reduced pressure in a water bath at 37°C using a 
rotary evaporator. 
4. When dried, 1-2 ml methanol was added to rinse the inside of the flask, then rotavaped 
again to dry this off. This was done twice to draw off any residual water in the sample. 
5.  The dried whole lipid extract was removed into a 10 ml vial using 3 x 2 ml washes of 
C/M + BHT. (6ml). 
6. The volume was reduced to about 1 ml under a stream of OFN at 37°C and Stored at 
4°C or -20°C until needed. 
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Thin layer chromatography (TLC): 
                         Solvents 
For phospholipid separations: C/M/M (chloroform, methanol, methylamine, 65:35:15 + 
BHT @ 100mg/l). 
                       TLC Tanks 
 Lined with filter paper and containing about 150-200 ml of solvent, well-fitting lid. The 
tank was allowed to equilibrate for at least 30 minutes before use. 
 TLC plates 
20 cm square plates coated with silica gel were used Application 
Application 
 
 
Figure (2-1) application of samples in TLC plate 
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The samples were concentrated under a stream of OFN, and then applied to the plate 
using capillary tubes in a uniform line about 2 cm above the bottom of the plate, as 
narrow as possible. 
                         Running 
 The plates were put in the tank without disturbing the equilibrium of the atmosphere 
inside. A good seal was ensured. When the solvent front has reached the line scored at the 
top of the plates, the plates were left for further 10 minutes, to improve the definition of 
the bands.( Phospholipid plates take about 90 minutes to run). 
                       Visualisation 
A after the plates, were removed from the TLC tank, they were dried in a hot air stream 
(hair dryer) and sprayed (in fume cupboard) with a 0.1% solution of 
2,7-dichlorofluoroscein in methanol until the plates were lightly and evenly coated. The 
bands were Visualise under UV light, using glass goggles or a glass plate, for protection 
and marked with a soft pencil and compared with standard plates to identify the different 
bands. 
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Figure (2-2) visualization of lipid bands under UV light 
                        Scraping 
The appropriate bands were scraped onto filter paper using a blunt instrument (flat 
spatula) and transferred to a methylating tube. 
Methylation:  
The methylating reagent, 15% acetyl chloride in methanol, must be prepared freshly as 
follows: 
 Add, dropwise, 15 ml acetyl chloride to 100 ml dry methanol in a 500 ml conical flask 
while swirling the flask under a stream of cold water. Wear a facemask and a fully 
buttoned lab coat. Do not let the acetyl chloride boil in the methanol. Do not let water 
splash into the flask. Transfer the mixture to a stoppered bottle. BHT is not used during 
methylation as it appears to generate decomposition products.  
1. For formation of fatty acids methylesters, 15% acetyl chloride in methanol was used. It 
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is also possible to use ethanol or propanol, which produce the less volatile and slower-
running ethyl and propyl esters. The GC relative retention times (RRTs) are unchanged - 
that is the RRT of 18:1 ethyl ester to 18:0 ethyl ester is the same as for the corresponding 
methyl esters - they just run more slowly. This makes ethylation/propylation good for 
short chain FA, but not so good for the long chain polyunsaturated fatty acids.  
2. To the bands scraped from the TLC plates, approximately 4 ml of the methylating 
reagent (above) was added.  
3. Flushing thoroughly by bubbling OFN through the liquid, with cap held over neck of 
tube and Vortexing were done. 
4.  The level of the liquid in the tube was marked with a pen. 
    5. Methylation at 70 degrees for three hours. At 1 and 2 hours checking that the level has 
not decreased. If it has, change the cap (and the tube if the lip is cracked or chipped), and 
make up the volume with methanol and reflush. Vortexing the tubes before putting them 
back in the oven was done. 
Extraction of methyl esters: 
1. The tubes then removed from the oven and let to cool to room temperature. 
To each tube 4 ml 5% saline were added and 2 ml petrol spirit + BHT, Capped and 
shacked well. This will form two layers. 
2. The upper petrol layer was removed to a test-tube containing 2 ml 2% potassium 
bicarbonate (to neutralise any acid transferred). 
3. Vortexing the petrol extract with the bicarbonate was done and the upper, petrol layer 
transferred to a test- tube containing 100-200 mg dried granular sodium sulphate, to 
remove any residual water. 
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4. The solution of fatty acid methyl esters in petrol was removed to a 3 ml vial. 
5. The petrol was removed under a stream of OFN. The sample was taken up in 1 ml 
heptane + BHT, flushed with OFN and stored at -20  C until ready for GC. 
The individual fatty acids in the samples were identified by comparing them with 
standards of known retention time (time which is taken by the fatty acid sample to appear 
as a certain wave in the soft ware after injection in the GC). 
All the samples were loaded over night in patches; each patch consists of 30 samples in 
the sample plate with an auto sampler (Fisons A 2005). 
Specifications of the gas chromatography machine: 
MEGA 2 series, model EL 980 from Fisons S.P.A Company, Melano, Italy, equipped 
with flame ionized detector (FID), and soft-ware system from Hewlett-packard 
(Germany). The carrier gas or mobile phase was hydrogen which was produced from 
water with a hydrogen generator (2007 Whatman). 
Gas chromatography: 
Sample preparation for gas chromatography: 
25 drops of the sample was transferred to the GC brown vial, dried under a steam of 
oxygen free nitrogen (OFN) at 37 °C . Then 3 drops of heptane +BHT was added to make 
the appropriate sample concentration for the run in the GC, the vial was then tightly 
capped and Loaded onto the auto sampler 
 
 
 
. 
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Figure (2-3) gas chromatogram showing fatty acid peaks 
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2.8.4 Retinol and α-tocopherol: 
 
Extraction of retinol, Vitamin E in Human Plasma: 
1. 500µl of plasma  was deproteinized with 500µl of 100% ethanol and  
            vortexed for five minutes. 
2. Then 1.5 ml of chloroform was added to extract the fat soluble vitamins, 
retinol and α-tocopherol in the plasma sample. 
3. Again the mixture was vortexed for 5minutes before centrifugation for further 
8 minutes at 4000 rpm at 25 degrees. 
4. The organic layer containing the vitamins was then removed and further 
extraction was done with 1ml of chloroform. (Repeated twice). 
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5. Evaporation of the vitamins extract to dryness was done under oxygen free 
nitrogen. 
6.  The dried extract was dissolved in 100µl of 98% methanol, and transferred 
into HPLC brown vials. 
7.  The HPLC vials containing the purified vitamins mixture were then stored at 
-20 degrees when not used in the same day. 
2.9 HPLC system: 
The HPLC system used for analysis of the vitamins retinol and α-tocopherol was a 
reverse phase system (Alligent 1100 series) in which 98% HPLC grade methanol 
(Fisher scientific UK) was used as the mobile phase, in addition to 2% deionized 
water. The flow rate of the mobile phase was 1ml/minute. 
The purities of vitamin standards which were used were 99% for retinol, 97% for α-
tocopherol (Sigma Aldrich). 
2.9.1Column specifications: 
The column was made of C 18 Hypersil gold, 250 mm in length and with a diameter 
of 4.6 mm (Therma scientific). 
 2.9.2 Detector: The system uses a photodiode-array detector, which identified the 
vitamins in the following wave lengths; 293nm for α-tocopherol, 326 nm for retinol. 
System soft-ware: The soft ware used in the HPLC system was from Hewlett-
packard (Germany). 
2.9.3 Auto sampler: 
 The system contained auto sampler with its plate for sample loading (Agillent 1100 
series). 
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2.10 Statistics 
Data was entered in computer using SPSS for windows and double checked before 
analysis. The mean (SD) of the basic characteristics were compared between the two 
groups using student t-test. Data were checked for normality, in normally distrubuted 
data student t-test and ANOVA were used to compare two and more groups 
resepctiely, if the data were not normally distributed; Mann-Whitney U test was used 
to determine the significance of difference between the variables. Correlations 
between continuous variables were assessed by the Spearman rank test. P< 0.05 was 
regarded as significant 
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Chapter Three 
 
Results  
 85
Results:  
This is a case-control study comprising 98 Sudanese women with preeclampsia, and 92 
healthy pregnant women, both in the third trimester. The study aimed to evaluate the role 
of cytokines imbalance and oxidative stress in the pathogenesis of precclampsia. 
3.1 Cytokines profiles: 
 Table (3.1), shows the clinical characteristics of patients with preeclampsia and the 
control group. The two groups were well matched in their age, gravidity, gestational age 
and weight.  
Data for cytokines was not normally distributed, the median and interquartile ranges were 
used and Mann-Whitney U test was used to compare the significance of difference 
between the variables. 
Table (3.2) shows that the levels of IFN-γ and IL-4 were slightly -not statistically 
significant- higher in the women with preeclampsia. IL-10 was significantly higher in the 
women with preeclampsia; Women with preeclampsia had significantly lower levels of 
IFN-γ and IL-4 and significantly higher levels of IL-10 7days later in comparison with 
the presenting levels, table (3.3). 
Correlation between the three cytokines at presentation: 
 Positive correlation was observed between IL-4 and IFN-γ r=0.495, P< 0.007, also 
between IL-4 and IL-10 r=0.445, P< 0.009.  IL-10 and IFN-γ were not positively 
correlated r=0.094, P < 0.602. 
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Table (3-1) Clinical characteristics of patients with preeclampsia and the control group 
 
 variables Women with preeclampsia
(n=33) 
    Control (n=32)    P value 
  age  29.5(5.7)   29.5(5.90       0.9 
 
   gravidity   2.1(2.1)    1.8(1.9)       0.3 
   Gestational        
age, weeks 
  35.2(2.8)    35.6(2.9)        0.5 
  Weight, kg   59.7(7.4)    57.(6.8)         0.6 
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Table (3.2): The median and interquartile of cytokines in cases and control group 
 
Cytokine 
Pg/ml 
Case (n=33) Control (n=32) 
 
P 
IFN-γ 210 (142.40-287.06) 125.38 (85.67-184.95) 0.437 
IL-4 10.3 (3.33-18.35) 9.69 (3.69-14.63) 0.780 
IL-10 8.6 (2.39-16.66) 6.99 (3.39-16.84) 0.002 
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Table (3.3) the median and interquartile of cytokines in patients with pre-eclampsia  
at presentation and day seven. 
 
Cytokine 
Pg/ml 
  At presentation           Day seven  P  
IFN-γ 210.48 (142.40-287.06) 136.73 (81.42-192.04) 0.035 
IL-4 10.36 (3.33-18.35) 9.99 (2.15-15.36) 0.000 
IL-10 8.61 (2.93-16.66) 10.63 (6.18-25.41) 0.000 
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3.2 antioxidant enzymes: 
The two groups were well matched and there was no statistical difference concerning age, 
parity, gestational age and weight, table (3.2.1). 
Data for antioxidant enzymes was not normally distributed, the median and interquartile 
ranges were used and Mann-Whitney U test was used to compare the significance of 
difference between the variables. 
The activity levels of the three enzymes (glutathione peroxidase, catalase and superoxide 
dismutase) were slightly (not statistically significant) higher in preeclamptic women 
compared to the control group, table (3.2.2)  
This was also true- the slightly higher levels of erythrocyte glutathione peroxidase  and 
slightly lower levels of the other tow enzymes catalase and superoxide dismutase -when 
the women with mild (diastolic blood pressure < 110 mmHg) and severe preeclampsia 
(diastolic blood pressure ≥ 110 mmHg) were compared, table (3.2.3) 
A significantly negative correlation was observed between the activity of glutathione 
peroxidase and diastolic blood pressure r= -0.371, P = 0.02. There was no significant 
correlation between catalase (r= - 0.033, P = 0.840) or superoxide dismutase r = 0.067, P 
= 0.676 and diastolic blood pressure. 
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Table (3.2.1): Clinical characteristics of preeclamptic and normal pregnant women 
 
Characteristics Preeclamptic women Control women P. value 
Age, years 28.98 ( 5.64) 27.88 (5.28) 0.2 
Gestational age,  33.74 (2.83) 34.37 (3.04) 0.234 
Parity 2.4(1.93) 2.23 (1.42) 0.581 
Weight, kg 67.86 (12.10) 69 (13.34) 0.531 
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Table (3.2.2): Median (25-75 quartiles) levels of activities of erythrocyte glutathione 
peroxidase, catalase, and superoxide dismutase in women with preeclampsia and the 
control group 
 
Enzyme 
U/ml 
Case Control P 
value 
Glutathione peroxidase 416 (340-450) 359(307.5-432) 0.106 
Catalase 62.2 (37.2-80.0) 52.6(45.7-59.8) 0.276 
Superoxide dismutase 2824(2271-2987) 2550 (2309-2729) 0.104 
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Table (3.2.3): Median (25-75 quartiles) levels of activities of erythrocyte glutathione 
peroxidase, catalase, and superoxide dismutase in women with mild and severe 
preeclampsia  
 
Enzyme 
U/ml 
Mild preeclampsia Severe preeclampsia P value 
Glutathione peroxidase 426(340-512) 399(334.5-436.5) 0.2 
Catalase 59.2(31.4-83.3) 62.8(37.5-78.3) 0.8 
Superoxide dismutase 2706(2238-2941.7) 2873(3209-3031) 0.6 
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3.3: Results of omega-3 (ecosapentaenoic acid –EPA-, docosahexaenoic acid –DHA-)and 
omega-6 (arachidonic acid –AA-) fatty acids profiles in three fractions of red blood cell 
membrane phospholipids, namely phosphatidylethanolamine (PE), phosphatidylcholine 
(PC) and sphyngomyelins (SM) in Sudanese women with preeclampsia (mild and severe) 
and the control group: 
The two groups were well matched and there was no statistical difference concerning age, 
parity, gestational age and weight, table (3.3.1). 
The fatty acid data was normally distributed in the PE fraction, and the T-test was used. 
1. Phosphatidylethanolamine fraction (PE): 
a. The mean level of EPA was significantly higher in women with preeclampsia (n = 
65) than the control group (n = 60), P = 0.012, but when the level was compared 
between women with severe preeclampsia (DBP> or = 110 mmHg), (n=25) and 
mild preeclampsia (DBP<110 mmHg), (n=40) it was slightly higher although not 
statistically significant in women with severe preeclampsia, P = 0.688.  
b. The mean level of DHA was significantly higher in women with preeclampsia 
(n=65) than the control group (n=60), P= 0.04, but was not significantly different 
when cases with mild and severe preeclampsia were compared, P = 0.489. 
c. The mean level of arachidonic acid (AA) was slightly higher in the control group, 
but the difference was not statistically significant, P = 0.308. When cases of mild 
and severe preeclampsia were compared, the mean level although higher in cases 
with severe preeclampsia, was not statistically significant, P = 0.484. 
      Tables: (3.3.2), (3.3.3). 
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Table (3.3.1): Clinical characteristics of preeclamptic and normal pregnant women 
 
Characteristics Preeclamptic women Control women P. value 
Age, years 28.98 ( 5.64) 27.88 (5.28) 0.2 
Gestational age,  33.74 (2.83) 34.37 (3.04) 0.234 
Parity 2.4(1.93) 2.23 (1.42) 0.581 
Weight, kg 67.86 (12.10) 69 (13.34) 0.531 
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Table (3.3.2): Mean (SD) levels of EPA, DHA and AA in women with preeclampsia and 
the control group in the PE fraction. 
Variable 
% of total fatty 
acids 
case control P 
Ecosapentaenoic 
acid (EPA) 
0.1437(0.0381) 
n=65 
0.1275(0.0322) 
n=59 
 
0.012 
Docosahexaenoic 
acid (DHA) 
5.1372(0.9087) 
n=65 
4.0848(0.8780) 
n=60 
 
0.04 
Arachidonic acid 
(AA) 
20.2205(1.4532) 
n=65 
20.4637(1.1655) 
n=60 
 
0.308 
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Table: (3.3.3) Mean (SD) levels of omega-3 and omega-6 fatty acids in 
phosphatidylethanolamine (PE) in mild and severe preeclampsia: 
 
 
Variable 
% of total fatty 
acids 
 
Mild preeclampsia 
DBP<110 mmHg 
n=40 
Severe preeclampsia 
DBP>=110 
n=25 
 
P 
Ecosapentaenoic 
acid (EPA) 
 
0.1422(0.0371) 
 
0.1461(0.0404) 
 
0.688 
Docosahexaenoic 
acid (DHA) 
 
5.1994(1.0498) 
 
5.0376(0.6283) 
 
0.489 
Arachidonic acid 
(AA) 
 
20.1197(1.4056) 
 
20.3817(1.5416) 
 
0.484 
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2. Phosphatidylcholine fraction (PC): 
     The fatty acid data was also normally distributed in the PC fraction, and the T-test was   
used. 
a. The mean level of EPA was significantly higher in women with preeclampsia (n = 
62) than the control group (n = 52), P = 0.000, but in the group of women with 
preeclampsia, the difference was not statistically significant when women with mild 
and severe preeclampsia were compared, P = 0.615, although the level was slightly 
higher in women with severe preeclampsia.  
b. The mean level of DHA was significantly higher in women with preeclampsia 
(n=64) than the control group (n=60), P= 0.046, but was not significantly different 
when cases with mild (n=40) and severe (n=24) preeclampsia were compared,  
      P = 0.973. 
c. The mean level of arachidonic acid (AA) was slightly higher in the preeclampsia 
group (n=64), than the control (n=60) but the difference was not statistically 
significant, P = 0.671. When cases of mild (n=40) and severe (n=24) preeclampsia 
were compared, the mean level although higher in cases with mild preeclampsia, was 
not statistically significant, P = 0.469. 
Tables: (3.3.4), (3.3.5). 
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Table (3.3.4): Mean (SD) levels of EPA, DHA and AA in phosphatidylcholine (PC) 
among women with preeclampsia and the control group. 
 
Variable 
% of total fatty 
acids 
Case control P 
Ecosapentaenoic 
acid (EPA) 
0.0937(0.0352) 
n=62 
0.0663(0.0296) 
n=52 
 
0.000 
Docosahexaenoic 
acid (DHA) 
1.367(0.4160) 
n=64 
1.234(0.3140) 
n=60 
 
0.046 
Arachidonic acid 
(AA) 
8.1780(1.5310) 
n=64 
8.0760(1.0890) 
n=60 
 
0.671 
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Table (3.3.5): Mean (SD) levels of omega-3 and omega-6 fatty acids in 
phosphatidylcholine (PC) in mild and severe preeclampsia:  
 
Variable 
% of total fatty 
acids 
Mild preeclampsia 
DBP<110 mmHg 
Severe preeclampsia 
DBP>=110 
 
P 
Ecosapentaenoic 
acid (EPA) 
0.0919(0.0330) 
n=38 
 
0.0966(0.0389) 
n=24 
 
 
0.615 
 
Docosahexaenoic 
acid (DHA) 
1.3660(0.4194) 
n=40 
 
1.3696(0.4185) 
n=24 
 
 
0.973 
 
Arachidonic acid 
(AA) 
8.2865(1.5555) 
n=40 
 
7.9971(1.5055) 
n=24 
 
 
0.469 
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3. Sphyngomyelin fraction (SM): 
 
Fatty acid data including EPA, DHA and AA was not normally distributed, but was 
 
 converted to normally distributed data by taking log10 for each of them and the T-
test was used to compre the mean level between the women with preeclampsia and 
the control group, and mild and severe preeclampsia. 
a. The mean level of EPA was significantly higher in women with preeclampsia (n = 
62) than the control group (n = 59), P = 0.000, but in the group of women with 
preeclampsia, the difference was not statistically significant when women with mild 
(38) and severe (24) preeclampsia were compared, P = 0.138, although the level was 
slightly higher in women with severe preeclampsia.  
b. The mean level of DHA was significantly higher in women with preeclampsia 
(n=65) than the control group (n=60), P= 0.000, but was not statistically significantly 
different when cases with mild (n=40) and severe (n=24) preeclampsia were 
compared, P = 0.158. 
c. The mean level of arachidonic acid (AA) was significantly higher in the 
preeclampsia group (n=65), than the control (n=60), P = 0.000. When cases of mild 
(n=40) and severe (n=24) preeclampsia were compared, the mean level although 
higher in cases with severe preeclampsia, was not statistically significant, P = 0.475. 
Tables: (3.3.6), (3.3.7). 
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Table (3.3.6): Mean (SD) levels of EPA, DHA and AA in sphyngomyelin fraction among 
women with preeclampsia and the control group. 
 
Variable 
% of total fatty 
acids 
case control P 
Ecosapentaenoic 
acid (EPA) 
0.8503(0.1483) 
n=62 
 
0.3548(0.1398) 
n=59 
0.000 
 
Docosahexaenoic 
acid (DHA) 
0.0912(0.0353) 
n=65 
0.0356(0.0238) 
n=60 
0.000 
Arachidonic acid 
(AA) 
0.8421(0.1223) 
n=65 
0.2720(0.1226) 
n=60 
0.000 
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Table (3.3.7): Mean (SD) levels of omega-3 and omega-6 fatty acids in sphyngomyelin 
fraction (SM) in mild and severe preeclampsia. 
 
 
Variable 
% of total fatty 
acids 
Mild preeclampsia 
DBP<110 mmHg 
Severe preeclampsia 
DBP>=110 
 
P 
Ecosapentaenoic 
acid (EPA) 
0.8281(0.1696) 
n=38 
 
0.8856(0.0996) 
n=24 
 
0.138 
 
Docosahexaenoic 
acid (DHA) 
0.1401(0.0292) 
n=40 
 
0.0129(0.0127) 
n=24 
 
0.158 
 
Arachidonic acid 
(AA) 
0.8335(0.1159) 
n=40 
 
0.8560(0.1332) 
n=24 
 
0.475 
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3.4: Plasma antioxidant vitamins; retinol and α-tocopherol in plasma of women with 
preeclampsia and the control group, and in women with mild and severe 
preeclampsia: 
Data was not normally distributed, and hence quartiles (25th, 75th) and the median 
levels of each of the vitamins were used, Mann-Whitney U test was used to determine 
the significance of difference between the variables. 
1. 2. The median level of retinol was higher in the control group (n=58) than in 
plasma of women with preeclampsia (64), but the difference was not statistically 
significant, P = 0.297. 
When the level of retinol was compared between women with mild and severe 
preeclampsia, it was slightly higher in women with mild preeclampsia, but the 
difference was not statistically significant, P = 0.984. 
2. The median level of α-tocopherol was significantly higher in women with 
preeclampsia than the control group, P = 0.026. 
When the level of α-tocopherol was compared between women with mild and severe 
preeclampsia, it was slightly higher in those with mild preeclampsia, but the 
difference was not statistically significant, P = 0.618. 
Tables (3.4.1), (3.4.2). 
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Table (3.4.1): The median (interquartile range) of plasma retinol and α-tocopherol in 
women with preeclampsia and the control group. 
Variable  Women with 
preeclampsia 
n=64 
Control  
n=58 
P 
Retinol 
µgm/dl 
21.60 (15.750-
34.025) 
26.70 (16.225-
35.265) 
0.297 
α-tocopherol 
mg/dl 
8.60 (5.70-11.05) 
 
6.70 (3.45-9.40) 0.026 
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Table (3.4.2): The median (interquartile range) of plasma retinol and α-tocopherol in 
women with mild and severe preeclampsia. 
Variable  Women with mild 
preeclampsia 
 
Women with severe 
preeclampsia 
 
P 
Retinol 
µgm/dl 
21.80 (15.70-32.20) 
n=39 
21.50 (14.65-38.50) 
n=25 
0.984 
α-tocopherol 
mg/dl 
8.60 (6.825-10.875) 
n=40 
 
8.20 (2.75-11.25) 
n=25 
0.618 
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Chapter Four 
 
Discussion and conclusion 
 107
Discussion 
Pregnancy is a physiological state accompanied by a high metabolic demand and elevated 
requirements for tissue oxygen [247] and causes an increase of ROS production [248]. 
Moreover, the placenta is a major source of oxidative stress because of its enrichment 
with PUFA [249]. Falkay et al. [250] suggested that the increase in the lipid peroxide 
levels was due to the increased prostaglandin synthesis in the placenta. Lipid 
peroxidation is enhanced in the second trimester and tapers off later in gestation and 
decrease after delivery [251]. Monitoring of the oxidative stress in pregnant women is 
important to enable an understanding of the relationship between oxidative stress and 
pregnancy outcome [252]. Placental oxidative stress was suggested to play a role in the 
pathogenesis of pre-eclampsia [253, 254] and fetal growth retardation [254, 255]. On the 
other hand, the placenta is a source of antioxidative enzymes to control placental lipid 
peroxidation during healthy pregnancy. Placental production of lipid peroxides decreases 
as normal gestation advances, most likely because of an increase in the activity of 
superoxide dismutase and catalase [256]. Placental antioxidant defense is considered 
sufficient to control lipid peroxidation in healthy pregnancy [249]. 
This study was conducted to evaluate the role of cytokine (Th1/Th2) imbalance by 
studying serum interleukin 4 and 10 (IL-4 and IL-10) as examples of Th2 anti-
inflammatory cytokines and interferon gamma (IFN-γ) as an example of Th1 
inflammatory cytokine and oxidative stress which was assessed by unsaturated fatty acid 
(omega-3 and omega-6) profile in three fractions of red cell membrane phospholipids, 
namely; phosphatidyl ethanolamine, phosphatidyl choline and  sphyngomyelins, the level 
of plasma antioxidant vitamins, retinol and α-tocopherol and three erythrocyte 
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antioxidant enzymes, glutathione peroxidase, catalase and superoxide dismutase, in the 
pathogenesis of preeclampsia in pregnant Sudanese women in the third trimester 
compared to well matched pregnant controls. 
4.1 Cytokines profile in Sudanese women with preeclampsia 
Our finding of increased level of IFN-γ in the pre-eclamptic group at presentation was 
consistent with that of Alexander E. OMU etal [257] who has reported increased Th1 
cytokines in pre-eclampsia. But the rise was not statistically significant when compared 
to the control group, (P<0.305). This was further correlated with the pattern of Th1 
cytokines Production by decidual lymphocytes and peripheral mononuclear cells in 
patients with pre-eclampsia, as reported by Jonsson et. al 2005 [258]. At day seven 
(selected because it would be possible to catch patients in hospital at this period) the level 
of IFN-γ was significantly reduced (P< 0.035).  We have found a slightly increased level 
of IL-4 in pre-eclamptic women compared to the control group at presentation but the rise 
was not statistically significant (P<0.531), contrary to what had been reported by 
Alexander E. OMU etal [257] who have demonstrated that pregnancy is associated with 
modifications of TNF-α and IL-4 which are secreted by CD4+ T lymphocytes, and there 
is significantly higher increase of IL-4 (from 12-24 weeks) of gestation in normal 
pregnancy compared to pre-eclamptic pregnancy, this may be because our patients and 
the control group were selected in the third trimester of pregnancy, where the immune 
response may be different from the early and mid pregnancy; which is either due to 
gestational age difference or different pattern of steroid hormone release . At day seven 
the level of IL-4 was significantly reduced in the pre-eclamptic group (P< 0.035). 
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It has been suggested that the production of IL-4 in pregnancy may in fact have an 
important role in human gestation; it acts as a regulator of pro-inflammatory cytokines to 
prevent untimely delivery and modulate the role of Th1 cytokines in the pathophysiology 
of pre-eclampsia [259]. We also found a statistically significant rise in the level of IL-10 
in the preeclamptic group at presentation (P< 0.002) when compared to the control group, 
and at day seven in the pre-eclamptic group (P< 0.000). This was not correlated with the 
report of Orange S et al.,2003 [260] who reported low expression of Th2 cytokines IL-10 
and IL-5, our finding raises the possibility of a protective role of IL-10 in pre-eclampsia, 
because it antagonizes the effects of Th1 cytokines. 
Pr-eclampsia is associated with both local and systemic changes in type1/ type2 cytokine 
balance compared to normal pregnancy. Decidual and peripheral blood mononuclear cells 
from patients with pre-eclampsia are generally primed to synthesize high levels of the 
Th1 cytokines, [261]. On the other hand, they exhibit low expression of Th2 cytokines 
IL-10, and IL-5. These variations may be due to the unknown aetiology and 
pathophysiology of pre-eclampsia, and this raises a big question to be answered by 
further research in this field, whether these cytokines play an aetiologiacal role or their 
pattern of production is sequelae to other pathology. 
4.2 Antioxidant enzymes 
The main results of the study were; no significant differences in the levels of the three 
antioxidant enzymes; glutathione peroxidase, catalase and superoxide dismutase between 
women with preeclampsia (n=37) and controls (n=38), in between women with severe 
(n=17) and mild (n=19) preeclampsia. However, a significantly negative correlation was 
observed between the activity of glutathione peroxidase and diastolic blood pressure. 
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There was no significant correlation between catalase or superoxide dismutase and 
diastolic blood pressure. Similarly it has been found that preeclamptic women compared 
with women with normal pregnancy, have similar erythrocyte glutathione content, total 
plasma antioxidant capacity. According to these results, the authors concluded that, 
oxidative stress might not be a pathogenetically relevant process causally contributing to 
the disease [262]. In contrast, recently Patil and colleagues (2007) [263] reported that, 
enzymatic antioxidants namely superoxide dismutase, catalase, glutathione peroxidase 
and glutathione reductase were reduced significantly in preeclamptic women as compared 
to normal pregnant and non-pregnant controls. Furthermore, Bayahan, et al.,[264] 
reported that antioxidant enzyme activities (superoxide dismutase and glutathione levels) 
in erythrocytes were significantly decreased in women with preeclampsia and eclampsia 
compared with the controls. However, the later group [264] observed that, groups of 
preeclampsia and eclampsia had similar values of catalase activities as the controls and 
there were no correlations between antioxidant enzyme observed activities and systolic-
diastolic blood pressure of pregnant women with preeclampsia and eclampsia.  
 Anyway, oxidative stress has been proposed as a mechanism that contributes to 
endothelial dysfunction in preeclampsia. Lipid peroxidation is considered as a main 
feature of oxidative stress which may change membrane integrity and/or functions. It can 
be assessed in several ways such as estimation of levels of end products of peroxidation 
or antioxidants like enzymes, vitamins and minerals [265]. Arguably, the most important 
event during normal placental development is establishment of an effective maternal 
circulation, a process that is linked with the physiological conversion of the spiral arteries 
from highly tortuous and thick-walled vessels to flaccid sinusoidal conduits of low 
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resistance [266].  Failure of spiral artery remodeling in the placental bed of pregnancies 
affected by preeclampsia was first demonstrated by Brosens et al [267] and later 
associated with a partial failure of placental trophoblast invasion [268]. These 
observations are fundamental to the current theory of preeclampsia. More recently, it was 
shown in normal pregnancy that at 10 to 12 weeks’ gestation, the onset of maternal blood 
flow in the placenta results in a local increase in oxygen tension and parallel elevation in 
expression and activity of several antioxidant enzymes [269]. I t was  hypothesized that a 
putative diminution of the antioxidant response to this oxygenation stimulus could result 
in oxidative stress that may lead to trophoblast degeneration and possibly contribute to 
impairment of trophoblast invasion and diminished remodeling of the spiral arteries. 
[269]. A defective response to an oxidant stimulus could therefore be one of the earliest 
events in preeclampsia. Whatever the cause of impaired trophoblast invasion, the 
resultant inadequacy of placental perfusion is likely to result in oxidative stress by the 
following potential mechanisms. Maintenance of the muscular coat of the spiral artery 
may lead to intermittent placental perfusion, because the spiral arteries would retain 
susceptibility to maternal humoral and neuronal constrictor influences [270]. Together 
with frequent thrombotic occlusion followed by clot dissolution, this may lead to a 
repeated hypoxia/reoxygenation insult in the affected placenta throughout pregnancy. 
Hypoxia/reoxygenation is a potent stimulus to the activation of xanthine oxidase, an 
important source of superoxide generation, which is abundantly expressed in 
cytotrophoblast, syncytiotrophoblast, and villous stromal cells [271].  As might be 
anticipated, placental tissue from women with preeclampsia demonstrates enhanced 
expression and activity of this enzyme [271]. Thus xanthine oxidase is likely to play a 
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fundamental role in free radical-induced tissue damage in the human placenta. In support 
of this, Hung et al have shown that in vitro hypoxia/ reoxygenation in normal third 
trimester placenta leads to free radical-induced tissue damage as evidenced by 
nitrotyrosine staining in trophoblast and activation of apoptotic pathways, both of which 
were preventable by addition of a free radical scavenger [118]. 
 Their study also supports the suggestion that as a result of underperfusion, aponecrotic 
processes could lead to deportation of syncytiotrophoblast microvesicles into the 
maternal circulation. These microparticles, normally present in the circulation in 
pregnancy, have been shown to increase in preeclampsia and have been directly linked to 
activation of maternal neutrophils, which in turn may contribute to activation of the 
vascular endothelium [64].  
The source of the lipid peroxides in preeclampsia is unknown, but it has been suggested 
that poorly perfused placental tissue may evoke the free radical production which can be 
the cause of generalized lipid peroxidation [272]. The root of the controversy may lie in 
the fact that definitive evidence for the involvement of free radicals in disease processes 
is hampered by the lack of comparative methods and, therefore, the difficulty of 
comparing published data to assess absolute levels of oxidative stress in vivo. Small and 
heterogeneous patient groups might also have been leading reasons for disagreement. It 
seems that variation in the activity of antioxidant enzymes in these different reports may 
be the result of genetic variability between different populations, and further studies are 
needed to investigate this in more depth and to explore the genetic background of 
preeclampsia too. 
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4.3 Erythrocyte omega-3 and omega-6 fatty acids profiles: 
The main findings regarding omega-3 and omega-6 fatty acids profiles in the three 
phospholipids fractions of erythrocyte membrane; phosphatidyl ethanolamine (PE), 
phosphatidyl choline (PC) and phyngomyelins, were; 
 In the PE fraction we found significantly higher level of omega-3 fatty acids (EPA and 
DHA) in women with preeclampsia and insignificant difference in their level when cases 
with mild and severe preeclampsia were compared. There was no statistically significant 
difference in the level of arachidonic acid (omega-6 fatty acid), neither between the cases 
and controls, nor among women with mild and severe preeclampsia.  
In the PC fraction there was significantly higher level of omega-3 fatty acids (EPA and 
DHA) in women with preeclampsia and insignificant difference in their level when 
women with mild and severe preeclampsia were compared. There was no statistically 
significant difference in the level of arachidonic acid (omega-6 fatty acid), between 
women with preeclampsia and the controls, and among women with mild and severe 
preeclampsia. 
In the sphyngomyelin fraction there was significantly higher level of omega-3 (EPA and 
DHA) and omega-6 fatty acids in women with preeclampsia and insignificant difference 
in their levels when women with mild and severe preeclampsia were compared. 
Contrary to our findings, investigators have previously shown that derangements in 
omega-3 and omega-6 fatty acids in plasma phospholipids or erythrocytes are associated 
with preeclampsia and other adverse pregnancy outcomes [243-246]. Similarly, Williams 
et al. 1995 [245] reported in line with our current findings in PC and sphyngomyelin 
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fractions concerning omega-6 fatty acids, in their study of predominately white women in 
Seattle (Washington, USA)  that low erythrocyte levels of omega-3 fatty acids and high 
levels of omega-6 fatty acids, particularly arachidonic acid, were associated with an 
increased risk of preeclampsia. 
K.Mahomed et. al 2006 [273] in their report on association between maternal erythrocyte 
omega-3, omega-6 and trans fatty acids and risk of preeclampsia, found women in the 
highest quartile group for total omega-3 fatty acids compared with women in the lowest 
quartile experienced a 14 % reduction in risk of preeclampsia.  
They found little support for the hypothesized inverse association between omega-3 fatty 
acids and preeclampsia risk in their study population. There was some evidence 
suggestive of a weak positive association between increasing levels of arachidonic acid 
and risk of preeclampsia. In our study in the PE fraction, the level of arachidonic acid 
was slightly higher in the control group, but in PC and SM fractions, the level was 
slightly higher in women with preeclampsia although not statistically significant, which 
can not be considered as a strongly associated finding. We did not even find significant 
difference in the level of arachidonic acids, EPA or DHA between women with mild and 
severe preeclampsia. The raised level of omega-3 fatty acids (EPA and DHA) in the three 
phospholipids fractions in women with preeclampsia in our study does not support 
oxidative stress as an aetiological factor in preeclampsia, but the raised level of 
arachidonic acid in the sphyngomyelin fraction in women with preeclampsia is in line 
with the findings of K.Mahomed et. al 2006 [273], who relate omega-6 fatty acid to the 
risk of preeclampsia. 
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4.4 Antioxidant vitamins: 
The main finding regarding antioxidant vitamins was that, the median level of retinol was 
higher in the control group compared to women with preeclampsia, and in women with 
mild preeclampsia than those with severe preeclampsia, although the difference was not 
statistically significant. The median level of α-tocoferol was significantly higher in 
women with preeclampsia than the control group, P = 0.02, and insignificantly higher in 
women with mild than those with severe preeclampsia. In contrary to our finding, Burton, 
1994, [169] reported lower plasma Vitamin E in patients with pregnancy induced 
hypertension (PIH). Also no benefit was observed when vitamin E was supplemented in 
two studies to women with established preeclampsia [177, 178]. Chappell et al. 1999, 
[179] reported 8% incidence of preeclampsia in women with increased risk of 
preeclampsia that were supplemented with vitamin E, compared to 17% incidence in the 
placebo group. 
Our finding of higher plasma retinol level in the control group although insignificant is in 
line with a previous report of many observational studies that found a significant decrease 
in vitamin A and β-carotene in pre-eclamptic women when compared with normal 
pregnant women. This decrease was found both in serum [215-218] as well as amniotic 
fluid [219]. 
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Conclusion 
Preeclampsia is one of the life threatening complications during pregnancy in Sudan.Our 
results support the hypothesis of cytokine imbalance as a pathogenic factor for 
preeclampsia. The significantly raised levels of IL-10 in women with preeclampsia 
suggest its role in pathogenesis of preeclampsia as it is an anti-inflammatory Th2 
cytokine that is raised as a compensatory factor for the raised Th1 cytokines. 
Regarding oxidative stress, there was no statistical difference between the level of 
antioxidant enzymes; glutathione peroxidase, catalase and superoxide dismutase in 
erythrocyte membranes in preeclamptic and the control groups. But the negative 
correlation between the diastolic blood pressure and the level of glutathione peroxidase 
may point to the involvement of oxidative stress in the severity of preeclampsia. 
There was no reduction in the level of omega-3 fatty acids in women with preeclampsia 
compared to the control group; this finding does not support oxidative stress as an 
aetiological factor for preeclampsia. 
The level of omega-6 fatty acid (arachidonic acid) was only reduced in preeclamptic 
patients in the PE fraction; this may not also support oxidative stress.  
The insignificantly raised level of the natural antioxidant vitamin retinol in the control 
group and the significantly higher level of the other antioxidant vitamin α-tocopherol in 
preeclamptic women are also not in favor of oxidative stress as an aetiological factor for 
preeclampsia.   
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Recommendations 
 
It is good to encourage pregnant ladies to increase the intake of foods rich in omega-3 
fatty acids especially docosahexaenoic acid (DHA), because we realized that its level in 
our study group is low compared to European values from samples analyzed by other 
students at the IBCHN laboratory. This fatty acid is important for brain development 
during pregnancy [274].  
Establishment of large multicentre research plans in the future for the in depth study of 
the life threatening, yet unknown preeclampsia. 
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Cytokines Profiles in Sudanese Women with Preeclampsia 
CByatkohkeiint ee tP arlo.files in Sudanese Women with Preeclampsia 
Khalid H. Bakheit, Nada K. Bayoumi, Ahmed M. Eltom, Mustafa I. Elbashir, and Ishag 
Adam 
Faculty of Medicine, University of Khartoum, Sudan 
 
Background. Cytokine imbalance in preeclampsia may be one of the etiological factors 
for preeclampsia. Objectives: The study was conducted to investigate interferon gamma 
(IFN-γ), interleukin-4 (IL-4) and interleukin-10 (IL-10) in preeclampsia. Enzyme-linked 
immunosorbent assay (ELISA) was used to measure the concentrations of these three 
pro-inflammatory cytokines in sera from 33 Sudanese women with preeclampsia (at 
presentation and 7 days later) and 32 women with normal pregnancy as a control group. 
Results. The levels of IFN-γ and IL-4 were slightly— not statistically significant— 
higher in the women with preeclampsia. IL-10 was significantly higher in the women 
with preeclampsia. Women with preeclampsia had significantly lower levels of IFN-γ and 
IL-4 and significantly higher levels of IL-10 7days later in comparison with the 
presenting levels. Conclusion. Thus, the significantly raised levels of IL-10 in women 
with preeclampsia suggest its role in pathogenesis of preeclampsia, and further research 
is needed. 
 
Keywords: Cytokines, Preeclampsia, Pathogenesis, Sudan. 
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Appendix 
Questionnaire 
Date..............................................................Serial No………….D0…………D7………. 
 
Name……………………………………..Age………….Residence…………………….. 
 
Occupation……………………………….Education…………………………………….. 
 
Tribe……………………………………..Contact No…………………………………… 
 
Gravidity………………………Parity……………Gestational age……………………… 
 
Weight………………BP…………………..Hb……………………………………gm/dl 
 
Urine albumin +1 (           ) ….……..+2 (              ) ………………….   > +2 (                 ) 
 
Antihypertensive treatment…………………………………………………………......... 
 
……………………………………………………………………………………………. 
 
Steroids…………………………………………………………………………………… 
 
Urea…………………………………………..creatinine………………………………… 
 
Uric acid………………………AST…………………ALT…………………………….. 
 
 
